WO2011136318A1 - アルツハイマー病の治療剤又は予防剤 - Google Patents
アルツハイマー病の治療剤又は予防剤 Download PDFInfo
- Publication number
- WO2011136318A1 WO2011136318A1 PCT/JP2011/060355 JP2011060355W WO2011136318A1 WO 2011136318 A1 WO2011136318 A1 WO 2011136318A1 JP 2011060355 W JP2011060355 W JP 2011060355W WO 2011136318 A1 WO2011136318 A1 WO 2011136318A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- group
- mmol
- reaction
- added
- Prior art date
Links
- 0 *C(*)(CC1)CCC1(C(F)(F)F)O Chemical compound *C(*)(CC1)CCC1(C(F)(F)F)O 0.000 description 8
- CVZFXNRQVRLORH-UHFFFAOYSA-N CCc(cc1)ccc1-c1c(-c(cc2)ccc2OC)nc(C(CC2)(CCC2O)O)[s]1 Chemical compound CCc(cc1)ccc1-c1c(-c(cc2)ccc2OC)nc(C(CC2)(CCC2O)O)[s]1 CVZFXNRQVRLORH-UHFFFAOYSA-N 0.000 description 1
- PGNRNNMLSQHTHF-UHFFFAOYSA-N Cc(cc1)ccc1-c1c(-c(cc2)ccc2OC)nc(C(CC2)(CC2(C(F)(F)F)O)O)[s]1 Chemical compound Cc(cc1)ccc1-c1c(-c(cc2)ccc2OC)nc(C(CC2)(CC2(C(F)(F)F)O)O)[s]1 PGNRNNMLSQHTHF-UHFFFAOYSA-N 0.000 description 1
- HUBMCXZMVGUFIY-UHFFFAOYSA-N Cc(cc1)ccc1-c1cc(C(CC2)(CCC22OCCO2)OC)n[n]1-c(cc1)ccc1Cl Chemical compound Cc(cc1)ccc1-c1cc(C(CC2)(CCC22OCCO2)OC)n[n]1-c(cc1)ccc1Cl HUBMCXZMVGUFIY-UHFFFAOYSA-N 0.000 description 1
- QHFRAWBLJBXHBZ-UHFFFAOYSA-N Cc(cc1)ncc1C(C#CC(CC1)(CCC11OCCO1)O)=O Chemical compound Cc(cc1)ncc1C(C#CC(CC1)(CCC11OCCO1)O)=O QHFRAWBLJBXHBZ-UHFFFAOYSA-N 0.000 description 1
- XAUSCVBYCQIOBZ-UHFFFAOYSA-N NC(C(CC1)CCC11OCCO1)=O Chemical compound NC(C(CC1)CCC11OCCO1)=O XAUSCVBYCQIOBZ-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Definitions
- the present invention relates to a therapeutic or preventive agent for Alzheimer's disease.
- Alzheimer's disease is a disease characterized by senile plaques, ⁇ -amyloid deposits, and neurofibrillary tangles in the cerebral cortex and subcortical gray matter, and is characterized by progressive cognitive decline (hereinafter, dementia).
- dementia progressive cognitive decline
- depression schizophrenia-like symptoms (delusions, hallucinations, etc.), agitation, aggressive behavior, and lethargy-like symptoms called apathy are also known (Non-patent Document 1).
- the prevalence of Alzheimer's disease increases with aging, and it is said that it reaches 40% or more at the age of 85 or older. Therefore, in Japan and other aging societies, the development of therapeutic agents for Alzheimer's disease is urgently needed. ing.
- Non-patent Document 3 As the therapeutic agent or preventive agent for dementia due to Alzheimer's disease, currently used are the inhibitor of cholinesterase, which is a degrading enzyme of acetylcholine, donepezil, rivastigmine, galantamine and tacrine.
- cholinesterase a degrading enzyme of acetylcholine, donepezil, rivastigmine, galantamine and tacrine.
- memantine an N-methyl-D-aspartic acid (hereinafter referred to as NMDA) receptor antagonist, is used in Europe and the United States (Non-patent Document 3).
- Non-Patent Document 4 Some existing Alzheimer's disease treatments have reported analgesic effects on neuropathic pain. For example, donepezil has been reported to show an analgesic effect on a rat neuropathic pain model (Non-Patent Document 4). In addition, memantine exhibits an analgesic effect on a rat diabetic neuropathic pain model (Non-Patent Document 5) and also exhibits an analgesic effect on patients with complex local pain syndrome, which is one of neuropathic pain. has been reported (Non-Patent Document 6).
- Patent Document 1 pyrazole derivatives having a sulfonyl group on the aromatic ring
- Patent Document 2 pyrazole derivatives acting on the estrogen receptor
- Patent Document 3 a pyrazole derivative (Patent Document 3) effective as an analgesic or neuropathic pain therapeutic agent is known, there is no report on the therapeutic effect of Alzheimer's disease.
- Non-patent Document 2 the dose of an existing cholinesterase inhibitor, which is a therapeutic agent for Alzheimer's disease, is limited due to concerns about side effects in organs such as the heart and intestine that are subject to autonomic innervation. For this reason, not only a sufficient treatment effect for Alzheimer's disease cannot be obtained, but the treatment effect tends to be attenuated by continuous use.
- an object of the present invention is to provide a therapeutic agent and a preventive agent for Alzheimer's disease that has an action of inhibiting or delaying the progression of Alzheimer's disease and maintains the therapeutic effect on Alzheimer's disease even when taken for a long time.
- the present invention relates to the general formula (I)
- the therapeutic agent or preventive agent of Alzheimer's disease which contains the cyclohexane derivative shown by these, its pharmacologically acceptable salt, or its prodrug as an active ingredient.
- A is a substituent represented by the general formula (IIa) or (IIb);
- R 1 and R 2 are each independently a hydrogen atom, a chlorine atom, a haloalkyl group having 1 to 3 carbon atoms, an alkyl group or an alkoxy group having 1 to 4 carbon atoms having 1 to 4 carbon atoms
- R 3 is R 4 is a fluorine atom, a hydroxymethyl group or a hydroxyl group
- R 5 and R 6 are each independently a hydrogen atom, a fluorine atom, or a haloalkyl having 1 to 3 carbon atoms.
- R 7 and R 8 are each independently a hydrogen atom or a fluorine atom, Y is an oxygen atom or a sulfur atom, and Z is a nitrogen atom or a methine group.
- R 1 and R 2 are preferably each independently a trifluoromethyl group, a methyl group or a methoxy group
- R 3 is a hydrogen atom
- R 4 is a hydroxymethyl group or a hydroxyl group
- R 5 and R 6 are each independently a hydrogen atom, a fluorine atom, a trifluoromethyl group, a carboxyl group, a methoxy group, a hydroxyl group, or an acetyloxy group (which together may form an oxo group) ) Is more preferable.
- the cyclohexane derivative of the present invention or a pharmacologically acceptable salt thereof or a prodrug thereof has an action of inhibiting or delaying the progression of Alzheimer's disease, and maintains a therapeutic effect against Alzheimer's disease even when taken for a long time. have.
- the cyclohexane derivative of the present invention has the general formula (I) [In the formula, A is a substituent represented by the following general formula (IIa) or (IIb); R 1 and R 2 are each independently a hydrogen atom, a chlorine atom, a haloalkyl group having 1 to 3 carbon atoms, an alkyl group or an alkoxy group having 1 to 4 carbon atoms having 1 to 4 carbon atoms, R 3 is R 4 is a fluorine atom, a hydroxymethyl group or a hydroxyl group, and R 5 and R 6 are each independently a hydrogen atom, a fluorine atom, or a haloalkyl having 1 to 3 carbon atoms.
- R 7 and R 8 are each independently a hydrogen atom or a fluorine atom
- Y is an oxygen atom or a sulfur atom
- Z is a nitrogen atom or a methine group.
- C1-C4 alkyl group refers to a straight-chain, branched, or cyclic alkyl group having 1 to 4 carbon atoms. For example, methyl, ethyl, n-propyl, isopropyl, cyclo A propyl group, a cyclopropylmethyl group, an n-butyl group, a sec-butyl group or a tert-butyl group can be mentioned.
- C 1-4 alkoxy group means a linear, branched, or cyclic alkyl-oxy group having 1 to 4 carbon atoms, such as methoxy, ethoxy, n-propyloxy, isopropyl Examples thereof include an oxy group, a cyclopropyloxy group, an n-butoxy group, a sec-butoxy group, and a tert-butoxy group.
- haloalkyl group having 1 to 3 carbon atoms means that some or all of the hydrogen atoms on the straight chain alkyl group having 1 to 3 carbon atoms are halogen atoms (halogen atoms are fluorine atoms, chlorine atoms, bromine atoms) And a monochloromethyl group, a monofluoromethyl group, a difluoromethyl group, a trifluoromethyl group, a trichloromethyl group, or a pentafluoroethyl group.
- C2-C5 alkylcarbonyloxy group means, for example, acetyloxy group, ethanoyloxy group, propanoyloxy group, isopropanoyloxy group, butanoyloxy group, isobutanoyloxy group or pivaloyloxy group Is mentioned.
- A is preferably general formula (IIa), Y is preferably an oxygen atom, and Z is preferably a methine group.
- R 1 is preferably a hydrogen atom, a chlorine atom, a trifluoromethyl group, a methyl group, an ethyl group, an n-propyl group, an isopropyl group, a methoxy group, an ethoxy group, an n-propyloxy group, or an isopropyloxy group.
- a methyl group, a methyl group, and a methoxy group are more preferable, and a methyl group is more preferable.
- R 2 is preferably a hydrogen atom, chlorine atom, trifluoromethyl group, methyl group, ethyl group, n-propyl group, isopropyl group, methoxy group, ethoxy group, n-propyloxy group, isopropyloxy group, and methoxy group Is more preferable.
- R 3 is preferably a hydrogen atom
- R 4 is preferably a hydroxymethyl group or a hydroxyl group, more preferably a hydroxyl group.
- R 5 includes hydrogen atom, fluorine atom, trifluoromethyl group, carboxyl group, methoxy group, ethoxy group, n-propyloxy group, isopropyloxy group, hydroxyl group, acetyloxy group, propanoyloxy group, butanoyloxy Group or an isobutanoyloxy group is preferable, a hydrogen atom, a hydroxyl group, or a carboxyl group is more preferable, and a hydroxyl group is more preferable.
- R 6 includes hydrogen atom, fluorine atom, trifluoromethyl group, carboxyl group, methoxy group, ethoxy group, n-propyloxy group, isopropyloxy group, hydroxyl group, acetyloxy group, propanoyloxy group, butanoyloxy group Group or an isobutanoyloxy group is preferable, a hydrogen atom or a hydroxyl group is more preferable, and a hydrogen atom is further preferable.
- R 5 and R 6 may be combined to form an oxo group.
- compound (I) Of the compounds represented by formula (I) or pharmacologically acceptable salts thereof (hereinafter referred to as compound (I)), preferred specific examples are shown in Table 1, but these do not limit the present invention. .
- “Pharmaceutically acceptable salt” refers to, for example, inorganic acid salts such as hydrochloride, sulfate, phosphate and hydrobromide, oxalate, malonate, citrate and fumaric acid. Salt, lactate, malate, succinate, tartrate, acetate, trifluoroacetate, maleate, gluconate, benzoate, ascorbate, methanesulfonate, p-toluenesulfonic acid Salts, organic acid salts such as cinnamate, inorganic base salts such as sodium salt, potassium salt, calcium salt, magnesium salt, ammonium salt, and methylamine salt, diethylamine salt, trimethylamine salt, triethylamine salt, pyridinium salt, triethanol Examples include organic base salts such as amine salts, ethylenediamine salts, and guanidine salts. Furthermore, the compound (I) may be formed as a hydrate, a solvate or a
- Compound (I) can be synthesized, for example, according to the production method described below.
- the symbols in each reaction formula have the same definitions as above unless otherwise specified.
- a commonly used protective group may be introduced, and the protective group may be removed as necessary after the reaction.
- the protecting group for the hydroxyl group include an alkyl group having 1 to 4 carbon atoms, a phenyl group, a trityl group, an aralkyl group having 1 to 4 carbon atoms (for example, benzyl group), an acyl group (for example, formyl group, acetyl group).
- a benzoyl group an aralkyl-carbonyl group having 7 to 10 carbon atoms (for example, benzylcarbonyl group), and a substituted silyl group (for example, trimethylsilyl group, triethylsilyl group, or tert-butyldimethylsilyl group).
- the protecting group for the carboxyl group include an alkyl group having 1 to 4 carbon atoms.
- a salt may be used as the raw material compound.
- the salt include the same salts as the above pharmacologically acceptable salts.
- the compound (I) obtained by the production method described below can be isolated and purified according to known means, and examples of the known means include solvent extraction, recrystallization, and chromatography.
- the compound (I) contains an optical isomer, a stereoisomer, a positional isomer, and a rotational isomer, each can be obtained as a single compound by a known synthesis method and separation method.
- Compound (Ic) is obtained by alkylating compound (Ia), and compound (Id) is obtained by alkylating compound (Ib).
- Compound (Ie) is obtained by acylating compound (Ia), and compound (If) is obtained by acylating compound (Ib).
- the alkylation reaction of compound (Ia) or compound (Ib) is generally performed by reacting compound (Ia) or compound (Ib) with an alkyl halide in a solvent in the presence of a base, and does not inhibit the reaction. Is appropriately selected.
- the solvent that does not inhibit the reaction include ethers such as tetrahydrofuran, 1,4-dioxane, ethylene glycol dimethyl ether, acetone, acetonitrile, or N, N-dimethylformamide, and a mixed solvent thereof may be used. .
- Examples of the base include alkali metal hydrogen carbonates such as sodium hydrogen carbonate and potassium hydrogen carbonate, alkali metal carbonates such as potassium carbonate and cesium carbonate, amines such as triethylamine, diisopropylethylamine and pyridine, potassium tert-butoxide Or sodium hydride is mentioned.
- alkali metal hydrogen carbonates such as sodium hydrogen carbonate and potassium hydrogen carbonate
- alkali metal carbonates such as potassium carbonate and cesium carbonate
- amines such as triethylamine, diisopropylethylamine and pyridine
- potassium tert-butoxide Or sodium hydride is mentioned.
- the amount of the base used is preferably 0.5 to 6 mol, more preferably 0.8 to 3 mol, per 1 mol of compound (Ia) or compound (Ib).
- the amount of the alkyl halide used is preferably 0.5 to 5 mol, more preferably 0.8 to 2 mol, relative to 1 mol of compound (Ia) or compound (Ib).
- the reaction temperature for the above alkylation reaction is preferably ⁇ 78 to 200 ° C., more preferably ⁇ 20 to 100 ° C.
- the reaction time of the above alkylation reaction varies depending on the reaction conditions, but is preferably 5 minutes to 78 hours, more preferably 30 minutes to 48 hours.
- the acylation reaction of compound (Ia) or compound (Ib) generally involves reacting compound (Ia) or compound (Ib) with an acylating agent such as an acid halide or acid anhydride in a solvent in the presence of a base. And a solvent that does not inhibit the reaction is appropriately selected.
- the solvent that does not inhibit the reaction include halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride, and 1,2-dichloroethane, and ethers such as tetrahydrofuran, 1,2-dimethoxyethane, and 1,4-dioxane.
- a mixed solvent of these may be used.
- Examples of the base include pyridine, triethylamine, diisopropylethylamine, N, N-dimethylaminopyridine, and the like.
- the amount of the above acid halide or acid anhydride to be used is preferably 0.5 to 3 mol, more preferably 0.8 to 1.5 mol, relative to 1 mol of compound (Ia) or compound (Ib).
- the amount of the base used is preferably 0.1 to 6 mol, more preferably 0.8 to 3 with respect to 1 mol of compound (Ia) or compound (Ib).
- the reaction temperature of the acylation reaction is preferably ⁇ 20 to 150 ° C., more preferably 0 to 100 ° C.
- the reaction time for the above acylation reaction varies depending on the reaction conditions, but is preferably 5 minutes to 72 hours, more preferably 30 minutes to 48 hours.
- Compound (Ih) can be obtained by fluorinating compound (Ig).
- the fluorination reaction of compound (Ig) is generally performed by reacting compound (Ig) with a fluorinating agent in a solvent, and a solvent that does not inhibit the reaction is appropriately selected.
- a solvent that does not inhibit the reaction include hydrocarbons such as octane, hexane, benzene, and toluene, halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride, and 1,2-dichloroethane, tetrahydrofuran, and 1,2-dimethoxy.
- examples thereof include ethers such as ethane and 1,4-dioxane, and alkyl nitriles such as acetonitrile.
- a mixed solvent thereof may be used.
- fluorinating agent examples include alkylaminosulfur trifluorides such as (dimethylamino) sulfur trifluoride (DAST) and bis (2-methoxyethyl) aminosulfur trifluoride acid.
- DAST dimethylamino sulfur trifluoride
- DAST bis (2-methoxyethyl) aminosulfur trifluoride acid
- the amount of the fluorinating agent used is preferably 0.25 to 20 mol, more preferably 0.5 to 4 mol, relative to 1 mol of compound (Ig).
- the reaction temperature of the above fluorination reaction is preferably ⁇ 20 to 150 ° C., more preferably 0 to 100 ° C.
- the reaction time of the above fluorination reaction varies depending on the reaction conditions, but is preferably 5 minutes to 72 hours, more preferably 30 minutes to 48 hours.
- Compound (Ij) can be obtained by fluorinating Compound (Ii).
- the fluorination reaction of compound (Ii) is generally performed by reacting compound (Ii) with a fluorinating agent in a solvent, and a solvent that does not inhibit the reaction is appropriately selected.
- a solvent that does not inhibit the reaction include hydrocarbons such as octane, hexane, benzene, and toluene, halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride, and 1,2-dichloroethane, tetrahydrofuran, and 1,2-dimethoxy.
- examples thereof include ethers such as ethane and 1,4-dioxane, and alkyl nitriles such as acetonitrile, or a mixed solvent thereof may be used.
- fluorinating agent examples include alkylaminosulfur trifluorides such as (dimethylamino) sulfur trifluoride (DAST) and bis (2-methoxyethyl) aminosulfur trifluoride acid.
- DAST dimethylamino sulfur trifluoride
- DAST bis (2-methoxyethyl) aminosulfur trifluoride acid
- the amount of the fluorinating agent used is preferably 0.25 to 20 mol, more preferably 0.5 to 4 mol, relative to 1 mol of compound (Ii).
- the reaction temperature of the above fluorination reaction is preferably ⁇ 20 to 150 ° C., more preferably 0 to 100 ° C.
- the reaction time of the above fluorination reaction varies depending on the reaction conditions, but is preferably 5 minutes to 72 hours, more preferably 30 minutes to 48 hours.
- Compound (Ik) and Compound (Il) can be obtained by reducing Compound (Ii).
- Step 7 The reduction reaction of compound (Ii) is generally performed by reacting compound (Ii) with a reducing agent in a solvent, and a solvent that does not inhibit the reaction is appropriately selected.
- a solvent that does not inhibit the reaction include hydrocarbons such as octane, hexane, benzene, and toluene, ethers such as tetrahydrofuran, 1,4-dioxane, ethylene glycol dimethyl ether, and diethyl ether, methanol, ethanol, isopropyl alcohol, and the like. Although alcohol is mentioned, you may use these mixed solvents.
- Examples of the reducing agent include sodium borohydride, lithium borohydride, diisobutylaluminum hydride, lithium aluminum hydride, lithium triethyl hydride, sodium bis (2-methoxyethoxy) aluminum hydride or borane complex.
- the amount of the reducing agent used is preferably 0.25 to 100 mol, more preferably 0.5 to 20 mol, relative to 1 mol of compound (Ii).
- the reaction temperature for the above reduction reaction is preferably ⁇ 78 to 150 ° C., more preferably ⁇ 78 to 100 ° C.
- the reaction time of the above reduction reaction varies depending on the reaction conditions such as the reaction temperature and the amount of the reducing agent, but is preferably 5 minutes to 72 hours, more preferably 30 minutes to 24 hours.
- Compound (Im) and compound (In) can be obtained by trifluoromethylating compound (Ii).
- Examples of the trifluoromethylating agent include organic silicon compounds such as (trifluoromethyl) trimethylsilane.
- the trifluoromethylation reaction using an organosilicon compound can be performed according to a method described in a known document (Journal of the American Chemical Society, 1989, Vol. 39, p. 393-395) or a method analogous thereto.
- Compound (SI) is obtained by allowing Wittig reagent (LI) to act on compound (Ii), followed by hydrolysis.
- a commercially available compound can be used as the Wittig reagent (LI), but it can also be synthesized according to a method obvious to those skilled in the art.
- Compound (Io) can be obtained by oxidizing compound (SI).
- the Wittig reaction of compound (Ii) is generally performed by reacting compound (Ii) with a Wittig reagent in a solvent in the presence of a base, and a solvent that does not inhibit the reaction is appropriately selected.
- a solvent that does not inhibit the reaction include hydrocarbons such as octane, hexane, benzene, and toluene, and ethers such as tetrahydrofuran, 1,4-dioxane, ethylene glycol dimethyl ether, and diethyl ether. May be used.
- Examples of the base include lithium diisopropylamide, potassium tert-butoxide, sodium hydride, phenyllithium, and tert-butyllithium.
- the amount of the base used is preferably 0.5 to 3 mol, more preferably 0.8 to 2 mol, relative to 1 mol of compound (Ii).
- the amount of compound (LI) to be used is preferably 0.5 to 3 mol, more preferably 0.8 to 2 mol, per 1 mol of compound (Ii).
- the reaction temperature of the Wittig reaction is preferably ⁇ 78 to 100 ° C., more preferably ⁇ 78 to 50 ° C.
- the reaction time of the above Wittig reaction varies depending on the reaction conditions such as the reaction temperature, but is preferably 5 minutes to 48 hours, more preferably 30 minutes to 24 hours.
- the hydrolysis reaction for obtaining the compound (SI) is carried out in a solvent that does not inhibit the appropriately selected reaction.
- the solvent that does not inhibit the reaction include ethers such as tetrahydrofuran, 1,4-dioxane and ethylene glycol dimethyl ether, alcohols such as methanol, ethanol and tert-butanol, acetonitrile or water, and a mixed solvent thereof. May be used.
- the concentration of the acid used in the above hydrolysis reaction is preferably 0.1 to 12M, and the amount used is preferably 1 mol to excess with respect to 1 mol of compound (Ii).
- Examples of the acid used for the hydrolysis reaction include inorganic acids such as hydrochloric acid and sulfuric acid, and organic acids such as acetic acid.
- the reaction temperature of the above hydrolysis reaction is preferably ⁇ 20 to 200 ° C., more preferably 0 to 100 ° C.
- the reaction time of the above hydrolysis reaction varies depending on the reaction conditions, but is preferably 5 minutes to 48 hours, more preferably 30 minutes to 24 hours.
- oxidizing agent used for the oxidation reaction of the compound (SI) include chromium (VI) -acetic acid, Jones reagent, sodium chlorite and the like.
- the above oxidation reaction can be carried out according to a method obvious to those skilled in the art.
- R 9 and R 10 are each independently a methyl group, an ethyl group, n- propyl group, an isopropyl group, n- butyl group, sec- butyl group or tert- butyl or a group, R 9 , R 10 together may form an ethylene group (—CH 2 CH 2 —) or a prepylene group (—CH 2 CH 2 CH 2 —), etc., and other symbols are as defined above. is there. ]
- Compound (Ii) can be obtained by deprotecting compound (Ip).
- Step 11 The deprotection reaction of compound (Ip) can be carried out according to a method described in publicly known literature (PROTECTIVE GROUPS IN ORGANIC SYNTHESIS (WILEY-INTERSCIENCE)) or a method analogous thereto.
- Compound (IIIb) can be obtained by chlorinating Compound (IIIa).
- Step 12 The chlorination reaction of compound (IIIa) is generally carried out by reacting compound (IIIa) with a chlorinating agent in a solvent, and a solvent that does not inhibit the reaction is appropriately selected.
- a solvent that does not inhibit the reaction include halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane, acetonitrile, or ethyl acetate, and a mixed solvent thereof may be used.
- chlorinating agent examples include N-chlorosuccinimide (NCS).
- the amount of the chlorinating agent used is preferably 0.5 to 2 mol, more preferably 0.8 to 1.2 mol, relative to 1 mol of compound (IIIa).
- the reaction temperature of the above chlorination reaction is preferably 0 to 200 ° C, more preferably 0 to 120 ° C.
- the reaction time of the above chlorination reaction varies depending on the reaction conditions such as the reaction temperature, but is preferably 5 minutes to 72 hours, more preferably 30 minutes to 48 hours.
- Compound (IIIa) is obtained by cyclization of compound (LII) and compound (SII).
- Compound (LII) may be a commercially available compound, but can also be synthesized according to methods obvious to those skilled in the art.
- Step 13 The cyclization reaction between compound (LII) and compound (SII) is generally performed in a solvent that does not inhibit the appropriately selected reaction.
- the solvent that does not inhibit the reaction include alcohols such as methanol, ethanol and isopropyl alcohol, halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride and 1,2-dichloroethane, tetrahydrofuran, 1,2-dimethoxyethane, Examples thereof include ethers such as 1,4-dioxane, benzene, toluene, acetic acid, and water, and a mixed solvent thereof may be used.
- the amount of compound (LII) used is preferably 0.5 to 1.5 mol, more preferably 0.8 to 1.2 mol, relative to 1 mol of compound (SII).
- a catalyst may be used for the cyclization reaction
- examples of the catalyst include organic bases such as triethylamine and pyridine, inorganic acids such as hydrochloric acid and sulfuric acid, and organic acids such as acetic acid.
- the amount of the catalyst used is preferably 0.1 to 3 mol per 1 mol of compound (SII).
- the reaction temperature for the cyclization reaction is preferably 0 to 200 ° C, more preferably 0 to 120 ° C.
- reaction time of the above cyclization reaction varies depending on reaction conditions such as reaction temperature, but is preferably 5 minutes to 72 hours, more preferably 30 minutes to 48 hours.
- Compound (IV) is obtained by deprotonation and oxidation of compound (SIII).
- the above oxidation reaction can be carried out according to a method described in known literature (Tetrahedron, 1989, 45, p. 5703-5742) or a method analogous thereto.
- Step 14 The deprotonation reaction and oxidation reaction of compound (SIII) are generally carried out by reacting compound (SIII) with a base and an oxidizing agent in a dehydrating solvent, and a solvent that does not inhibit the reaction is appropriately selected.
- a solvent that does not inhibit the reaction include hydrocarbons such as octane, hexane, and heptane, and ethers such as tetrahydrofuran, 1,4-dioxane, ethylene glycol dimethyl ether, and diethyl ether. May be.
- Examples of the base include butyllithium such as n-butyllithium, sec-butyllithium, and tert-butyllithium.
- the amount of the base used is preferably 0.8 to 5 mol, more preferably 0.9 to 3 mol, relative to 1 mol of compound (SIII).
- the amount of compound (LIII) used is preferably 0.8 to 5 mol, more preferably 0.9 to 3 mol, per 1 mol of compound (SIII).
- Examples of the oxidizing agent used in the above oxidation reaction include 3-phenyl-2- (phenylsulfonyl) -1,2-oxaziridine.
- the reaction temperature of the above deprotonation reaction and oxidation reaction is preferably ⁇ 78 to 150 ° C., more preferably 0 to 50 ° C.
- the reaction time of the above deprotonation reaction and oxidation reaction varies depending on the reaction conditions, but is preferably 5 minutes to 72 hours, more preferably 30 minutes to 48 hours.
- Compound (VI) can be obtained by solvolysis of compound (V) obtained by reacting compound (LIV) with compound (LV).
- Compound (LIV) and compound (LV) may be commercially available compounds, but can also be synthesized according to methods obvious to those skilled in the art.
- Step 15 The reaction between the compound (LIV) and the compound (LV) is generally performed in a dehydrated solvent in the presence of a base, and a solvent that does not inhibit the reaction is appropriately selected.
- a solvent that does not inhibit the reaction include hydrocarbons such as octane, hexane, benzene, and toluene, and ethers such as tetrahydrofuran, 1,4-dioxane, ethylene glycol dimethyl ether, and diethyl ether. May be used.
- Examples of the base include alkyl lithiums such as methyl lithium and n-butyl lithium, and salts of dialkyl amines such as lithium diisopropylamide, lithium bis (trimethylsilyl) amide, and potassium bis (trimethylsilyl) amide.
- the amount of the base used is preferably 0.8 to 5 mol, more preferably 0.9 to 3 mol, relative to 1 mol of the compound (LIV).
- the amount of the compound (LV) used is preferably 0.8 to 5 mol, more preferably 0.9 to 3 mol, relative to 1 mol of the compound (LIV).
- the reaction temperature between the compound (LIV) and the compound (LV) is preferably ⁇ 78 to 150 ° C., more preferably ⁇ 78 to 100 ° C.
- the reaction time between the compound (LIV) and the compound (LV) varies depending on the reaction conditions, but is preferably 5 minutes to 72 hours, more preferably 30 minutes to 48 hours.
- the solvolysis reaction is generally performed in a solvent in the presence of a base, and a solvent that does not inhibit the reaction is appropriately selected.
- a solvent that does not inhibit the reaction include alcohols such as methanol and ethanol, or water, and a mixed solvent thereof may be used.
- Examples of the base include potassium carbonate, sodium carbonate, potassium hydroxide, and sodium hydroxide.
- the amount of the base used is preferably 0.5 to 10 mol, more preferably 0.8 to 3 mol, per 1 mol of compound (V).
- the reaction temperature of the above solvolysis reaction is preferably ⁇ 20 to 150 ° C., more preferably 0 to 100 ° C.
- the reaction time of the above solvolysis reaction varies depending on the reaction conditions, but is preferably 5 minutes to 72 hours, more preferably 30 minutes to 48 hours.
- Compound (SIIa) is obtained by oxidizing compound (VII) obtained by reacting compound (VI) with compound (LVI).
- Compound (SIIa) can also be obtained by reacting compound (VI) with compound (LVII).
- compound (LVI) and compound (LVII) commercially available compounds can be used, but they can also be synthesized according to methods obvious to those skilled in the art.
- Step 17 and Step 18 The reaction of compound (VI) with compound (LVI) or compound (LVII) is generally performed in a dehydrated solvent in the presence of a base, and a solvent that does not inhibit the reaction is appropriately selected.
- a solvent that does not inhibit the reaction include hydrocarbons such as octane, hexane, benzene, and toluene, and ethers such as tetrahydrofuran, 1,4-dioxane, ethylene glycol dimethyl ether, and diethyl ether. May be used.
- Examples of the base include alkyl lithiums such as methyl lithium and n-butyl lithium, and salts of dialkyl amines such as lithium diisopropylamide, lithium bis (trimethylsilyl) amide, and potassium bis (trimethylsilyl) amide.
- the amount of the above base used is preferably 0.8 to 5 mol, more preferably 0.9 to 3 mol, relative to 1 mol of compound (VI).
- the amount of compound (LVI) used in step 17 or compound (LVII) used in step 18 is preferably 0.8 to 5 mol, more preferably 0.9 to 3 mol, relative to 1 mol of compound (VI).
- the reaction temperature of the reaction between the compound (VI) and the compound (LVI) in the step 17 or the compound (LVII) in the step 18 is preferably ⁇ 78 to 150 ° C., more preferably 0 to 50 ° C.
- reaction time of the reaction between compound (VI) and compound (LVI) in step 17 or compound (LVII) in step 18 varies depending on the reaction conditions, but is preferably 5 minutes to 72 hours, more preferably 30 minutes to 48 hours. .
- the oxidation reaction of compound (VII) is generally performed by reacting compound (VII) with an oxidizing agent in a solvent, and a solvent that does not inhibit the reaction is appropriately selected.
- a solvent that does not inhibit the reaction include hydrocarbons such as octane, hexane, benzene, and toluene, halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride, and 1,2-dichloroethane, tetrahydrofuran, and 1,2-dimethoxy.
- Examples include ethane, ethers such as 1,4-dioxane, alkyl nitriles such as acetonitrile, trifluoroacetic acid, pyridine, acetone, and the like, and a mixed solvent thereof may be used.
- oxidizing agent examples include commercially available reagents such as manganese dioxide, sulfur trioxide-pyridine, activated dimethyl sulfoxide, and desmartin reagent.
- the amount of the oxidizing agent used is preferably 0.5 to 3 mol, more preferably 0.8 to 2 mol, relative to 1 mol of compound (VII).
- the reaction temperature of the above oxidation reaction varies depending on the kind of the oxidizing agent, but is preferably -78 ° C to 100 ° C, more preferably -78 ° C to 40 ° C.
- the reaction time of the above oxidation reaction varies depending on the reaction conditions such as the type of oxidant and reaction temperature, but is preferably 5 minutes to 72 hours, more preferably 1 to 24 hours.
- Compound (IX) can be obtained by reacting Compound (VIII) with Compound (LVIII).
- Compound (VIII) and compound (LVIII) can be commercially available compounds, but can also be synthesized according to methods obvious to those skilled in the art.
- Step 20 The reaction between compound (VIII) and compound (LVIII) is generally performed in a dehydrated solvent in the presence of a base, and a solvent that does not inhibit the reaction is appropriately selected.
- a solvent that does not inhibit the reaction include hydrocarbons such as octane, hexane, benzene, and toluene, and ethers such as tetrahydrofuran, 1,4-dioxane, ethylene glycol dimethyl ether, and diethyl ether. May be used.
- Examples of the base include lithium diisopropylamide, lithium bis (trimethylsilyl) amide, and potassium bis (trimethylsilyl) amide.
- the amount of the above base used is preferably 0.8 to 4 mol, more preferably 0.9 to 3.5 mol, relative to 1 mol of compound (VIII).
- the amount of compound (LVIII) to be used is preferably 0.8 to 5 mol, more preferably 0.9 to 3 mol, per 1 mol of compound (VIII).
- the reaction temperature of the reaction between the compound (VIII) and the compound (LVIII) is preferably ⁇ 78 to 150 ° C., more preferably 0 to 50 ° C.
- the reaction time of the reaction between the compound (VIII) and the compound (LVIII) varies depending on the reaction conditions, but is preferably 5 minutes to 72 hours, more preferably 30 minutes to 48 hours.
- Compound (XI) can be obtained by oxidizing compound (X) obtained by reducing compound (IX).
- Step 21 The reduction reaction of compound (IX) is generally performed by reacting compound (IX) with a reducing agent in a solvent, and a solvent that does not inhibit the reaction is appropriately selected.
- Solvents that do not inhibit the reaction include hydrocarbons such as octane, hexane, benzene, and toluene, ethers such as tetrahydrofuran, 1,4-dioxane, ethylene glycol dimethyl ether, and diethyl ether, or alcohols such as methanol, ethanol, and isopropyl alcohol. A mixed solvent of these may be used.
- Examples of the reducing agent include lithium borohydride, diisobutylaluminum hydride, lithium aluminum hydride, lithium triethyl hydride, sodium bis (2-methoxyethoxy) aluminum hydride, and borane complex.
- the amount of the reducing agent used is preferably 0.25 to 100 mol, more preferably 0.5 to 20 mol, per 1 mol of compound (IX).
- the reaction temperature for the above reduction reaction is preferably ⁇ 78 to 150 ° C., more preferably ⁇ 78 to 100 ° C.
- the reaction time of the above reduction reaction varies depending on the reaction conditions such as the reaction temperature and the amount of the reducing agent, but is preferably 5 minutes to 72 hours, more preferably 30 minutes to 24 hours.
- the oxidation reaction of compound (X) is generally performed by reacting compound (X) with an oxidizing agent in a solvent, and a solvent that does not inhibit the reaction is appropriately selected.
- a solvent that does not inhibit the reaction include hydrocarbons such as trifluoroacetic acid, pyridine, acetone, octane, hexane, benzene, and toluene, and halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride, and 1,2-dichloroethane. , Tetrahydrofuran, 1,2-dimethoxyethane, ethers such as 1,4-dioxane, and alkyl nitriles such as acetonitrile, and a mixed solvent thereof may be used.
- oxidizing agent examples include commercially available reagents such as sulfur trioxide-pyridine, activated dimethyl sulfoxide, and desmartin reagent.
- the amount of the oxidizing agent used is preferably 0.5 to 3 mol, more preferably 0.8 to 2 mol, relative to 1 mol of compound (X).
- the reaction temperature of the above oxidation reaction varies depending on the kind of the oxidizing agent, but is preferably ⁇ 78 to 100 ° C., more preferably ⁇ 78 to 40 ° C.
- the reaction time of the above oxidation reaction varies depending on the reaction conditions such as the type of oxidant and reaction temperature, but is preferably 5 minutes to 72 hours, more preferably 1 to 24 hours.
- Step 23 Compound (XII) is obtained by converting compound (XI) to alkyne.
- the reagent used in the above conversion reaction include dimethyl-1-diazo-2-oxopropylphosphonate.
- the above conversion reaction can be carried out according to a method described in known literature (Tetrahedron Letters, 2006, 47, p. 1729-1731) or a method analogous thereto.
- Compound (SIIb) is obtained by oxidizing compound (XIII) obtained by reacting compound (XII) with compound (LVI).
- Compound (SIIb) can also be obtained by reacting compound (XVII) with compound (LVII).
- compound (LVI) and compound (LVII) commercially available compounds can be used, but they can also be synthesized according to methods obvious to those skilled in the art.
- Step 24 and Step 25 The nucleophilic addition reaction of compound (XII) is generally performed in a dehydrated solvent in the presence of a base, and a solvent that does not inhibit the reaction is appropriately selected.
- a solvent that does not inhibit the reaction include hydrocarbons such as octane, hexane, benzene, and toluene, and ethers such as tetrahydrofuran, 1,4-dioxane, ethylene glycol dimethyl ether, and diethyl ether. May be used.
- Examples of the base include alkyl lithiums such as methyl lithium and n-butyl lithium, and salts of dialkyl amines such as lithium diisopropylamide, lithium bis (trimethylsilyl) amide, and potassium bis (trimethylsilyl) amide.
- the amount of the base used is preferably 0.8 to 5 mol, more preferably 0.9 to 3 mol, relative to 1 mol of compound (XII).
- the amount of compound (LVI) used in step 24 or compound (LVII) used in step 25 is preferably 0.8 to 5 mol, more preferably 0.9 to 3 mol, relative to 1 mol of compound (XII).
- the reaction temperature of the above nucleophilic addition reaction is preferably ⁇ 78 to 150 ° C., more preferably 0 to 50 ° C.
- the reaction time of the above nucleophilic addition reaction varies depending on the reaction conditions, but is preferably 5 minutes to 72 hours, more preferably 30 minutes to 48 hours.
- the oxidation reaction of compound (XIII) is generally performed by reacting compound (XIII) with an oxidizing agent in a solvent, and a solvent that does not inhibit the reaction is appropriately selected.
- a solvent that does not inhibit the reaction include hydrocarbons such as trifluoroacetic acid, pyridine, acetone, octane, hexane, benzene, and toluene, and halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride, and 1,2-dichloroethane. , Tetrahydrofuran, 1,2-dimethoxyethane, ethers such as 1,4-dioxane, and alkyl nitriles such as acetonitrile, and a mixed solvent thereof may be used.
- oxidizing agent examples include commercially available reagents such as manganese dioxide, sulfur trioxide-pyridine, activated dimethyl sulfoxide, and desmartin reagent.
- the amount of the oxidizing agent used is preferably 0.5 to 3 mol, more preferably 0.8 to 2 mol, relative to 1 mol of compound (XIII).
- the reaction temperature of the above oxidation reaction varies depending on the kind of the oxidizing agent, but is preferably ⁇ 78 to 100 ° C., more preferably ⁇ 78 to 40 ° C.
- the reaction time of the above oxidation reaction varies depending on the reaction conditions such as the type of oxidant and reaction temperature, but is preferably 5 minutes to 72 hours, more preferably 1 to 24 hours.
- Compound (SIIIa) is a compound (XV) obtained by alkylating compound (XIV) with compound (LX) or acylating compound (XVI) obtained from compound (XIV) with compound (LXI). Is obtained by cyclization.
- Compound (XIV) and compound (LX) can be synthesized according to methods obvious to those skilled in the art.
- Compound (LXI) may be a commercially available compound, but can also be synthesized according to a method obvious to those skilled in the art.
- the alkylation reaction of compound (XIV) is generally performed by reacting compound (XIV) with an alkyl halide in a solvent in the presence of a base, and a solvent that does not inhibit the reaction is appropriately selected.
- a solvent that does not inhibit the reaction include ethers such as tetrahydrofuran, 1,4-dioxane, ethylene glycol dimethyl ether, acetone, acetonitrile, or N, N-dimethylformamide, and a mixed solvent thereof may be used.
- Examples of the base include alkali metal hydrogen carbonates such as sodium hydrogen carbonate and potassium hydrogen carbonate, alkali metal carbonates such as potassium carbonate and cesium carbonate, amines such as triethylamine, diisopropylethylamine and pyridine, potassium tert-butoxide Or sodium hydride is mentioned.
- alkali metal hydrogen carbonates such as sodium hydrogen carbonate and potassium hydrogen carbonate
- alkali metal carbonates such as potassium carbonate and cesium carbonate
- amines such as triethylamine, diisopropylethylamine and pyridine
- potassium tert-butoxide Or sodium hydride is mentioned.
- the amount of the base used is preferably 0.5 to 6 mol, more preferably 0.8 to 3 mol, relative to 1 mol of compound (XIV).
- the amount of compound (LX) to be used is preferably 0.5 to 5 mol, more preferably 0.8 to 2 mol, per 1 mol of compound (XIV).
- the reaction temperature for the above alkylation reaction is preferably ⁇ 78 to 200 ° C., more preferably ⁇ 20 to 100 ° C.
- the reaction time of the above alkylation reaction varies depending on the reaction conditions, but is preferably 5 minutes to 78 hours, more preferably 30 minutes to 48 hours.
- Step 28 Compound (XVI) can be synthesized from compound (XIV) according to a method obvious to those skilled in the art using, for example, thionyl chloride or oxalyl chloride.
- Step 29 The acylation reaction of compound (LXI) with compound (XVI) is generally performed in a solvent in the presence of a base, and a solvent that does not inhibit the reaction is appropriately selected.
- a solvent that does not inhibit the reaction include halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride, and 1,2-dichloroethane, and ethers such as tetrahydrofuran, 1,2-dimethoxyethane, and 1,4-dioxane.
- a mixed solvent of these may be used.
- Examples of the base include pyridine, triethylamine, diisopropylethylamine, N, N-dimethylaminopyridine, and the like.
- the amount of the base used is preferably 0.1 to 6 mol, more preferably 0.8 to 3 mol, relative to 1 mol of compound (XVI).
- the amount of compound (LXI) to be used is preferably 0.5 to 3 mol, more preferably 0.8 to 1.5 mol, per 1 mol of compound (XVI).
- the reaction temperature of the acylation reaction is preferably ⁇ 20 to 150 ° C., more preferably 0 to 100 ° C.
- the reaction time for the above acylation reaction varies depending on the reaction conditions, but is preferably 5 minutes to 72 hours, more preferably 30 minutes to 48 hours.
- the cyclization reaction of compound (XV) is generally performed in a solvent in the presence of an ammonium salt, and a solvent that does not inhibit the reaction is appropriately selected.
- a solvent that does not inhibit the reaction include acetic acid and formic acid, but a mixed solvent thereof may be used.
- ammonium salt examples include commercially available reagents such as ammonium acetate, ammonium formate, and ammonium carbonate.
- the amount of the ammonium salt used is preferably 1 to 20 mol, more preferably 2 to 15 mol, per 1 mol of compound (XV).
- the reaction temperature for the cyclization reaction is preferably 0 to 200 ° C, more preferably 50 to 120 ° C.
- the reaction time of the above cyclization reaction varies depending on the reaction conditions, but is preferably 5 minutes to 100 hours, more preferably 30 minutes to 48 hours.
- Compound (SIIIb) is cyclized using compound (LX) after compound (XVII) obtained by amidating compound (XIV) is converted to compound (XVIII) by subsequent thioamidation. Can be obtained.
- Compound (XIV) can be synthesized according to a method obvious to those skilled in the art.
- Compound (LX) can also be synthesized according to a method obvious to those skilled in the art.
- Step 31 The amidation reaction of compound (XIV) is generally performed by forming a mixed acid anhydride with chloroformate in a solvent in the presence of a base and then reacting with aqueous ammonia, and does not inhibit the reaction.
- the solvent that does not inhibit the reaction include ethers such as tetrahydrofuran, 1,4-dioxane, and ethylene glycol dimethyl ether, halogenated hydrocarbons such as dichloromethane and chloroform, and N, N-dimethylformamide.
- a solvent may be used.
- chloroformate examples include methyl chloroformate, ethyl chloroformate, isopropyl chloroformate, and sec-butyl chloroformate.
- the amount of the above-mentioned chloroformate used is preferably 0.5 to 4 mol, more preferably 0.9 to 2 mol, relative to 1 mol of compound (XIV).
- the base examples include inorganic bases such as sodium bicarbonate, sodium carbonate, potassium carbonate, cesium carbonate, and organic bases such as triethylamine, diisopropylmethylamine, and pyridine.
- the amount of the base used is preferably 0.5 to 5 mol, more preferably 0.9 to 2.5 mol, relative to 1 mol of compound (XIV).
- the reaction temperature of the above amidation reaction is preferably ⁇ 78 to 200 ° C., more preferably ⁇ 20 to 100 ° C. for the formation of the mixed acid anhydride.
- the reaction after addition of aqueous ammonia is preferably ⁇ 78 to 200 ° C., more preferably ⁇ 20 to 100 ° C.
- the reaction time of the amidation reaction described above varies depending on the reaction conditions, but the formation of the mixed acid anhydride is preferably 5 minutes to 48 hours, more preferably 30 minutes to 24 hours.
- the reaction after addition of aqueous ammonia is preferably 5 minutes to 72 hours, more preferably 30 minutes to 48 hours.
- Step 32 The thioamidation reaction of compound (XVII) is generally performed by reacting compound (XVII) with a commercially available reagent such as Lawesson's reagent or phosphorus pentasulfide in a solvent, and a solvent that does not inhibit the reaction is appropriately selected.
- a solvent that does not inhibit the reaction include saturated hydrocarbons such as benzene and toluene, halogen solvents such as dichloromethane and chloroform, and ethers such as tetrahydrofuran and 1,4-dioxane. Also good.
- the amount of Lawson reagent or phosphorus pentasulfide used is preferably 0.3 to 4 mol, more preferably 0.4 to 2 mol, relative to 1 mol of compound (XVII).
- the reaction temperature of the above thioamidation reaction is preferably ⁇ 20 to 200 ° C., more preferably 0 to 120 ° C.
- the reaction time of the above thioamidation reaction varies depending on the reaction conditions, but is preferably 5 minutes to 72 hours, more preferably 30 minutes to 48 hours.
- Step 33 The cyclization reaction of compound (XVIII) is generally performed in a solvent that does not inhibit the appropriately selected reaction.
- the solvent that does not inhibit the reaction include alcohols such as methanol and ethanol, ethers such as tetrahydrofuran and 1,4-dioxane, and acetonitrile, and a mixed solvent thereof may be used.
- the amount of compound (LX) to be used is preferably 0.5 to 4 mol, more preferably 0.9 to 1.5 mol, per 1 mol of compound (XVIII).
- the reaction temperature of the above cyclization reaction is preferably ⁇ 20 to 200 ° C., more preferably 0 to 100 ° C.
- the reaction time of the above cyclization reaction varies depending on the reaction conditions, but is preferably 5 minutes to 72 hours, more preferably 30 minutes to 48 hours.
- compound (I) When compound (I) is obtained in a free form, it can be converted to the target salt according to a known method or a method analogous thereto, and conversely, when it is obtained as a salt, According to an equivalent method, it can be converted to a free form or other desired salt.
- Compound (I) may be used as a prodrug, and as a prodrug of compound (I), for example, a compound that changes to compound (I) by a reaction with an enzyme, gastric acid or the like under physiological conditions in vivo, A compound that is enzymatically oxidized, reduced, hydrolyzed, etc. to change into compound (I), a hydroxyl group of compound (I) that is hydrolyzed by gastric acid, etc., and changed to compound (I) of the present invention Examples include acylated, alkylated, phosphorylated and borated compounds. Specific examples of preferred prodrugs of compound (I) are shown in Table 2, but these do not limit the present invention.
- the prodrug of compound (I) can be synthesized from compound (I) of the present invention according to a known method.
- prodrugs of Compound (I) are known in the literature ("Development of Pharmaceuticals", Hirokawa Shoten, 1990, Vol. 7, pp. 163 to 198 and Prog. Med. 5, 1985, pp. 2157 to 2161.
- the compound may be changed to the compound (I) under the physiological conditions described in (1).
- the medicament containing Compound (I) exhibits an excellent Alzheimer's disease therapeutic effect even when administered to mammals other than humans.
- mammals other than humans include mice, rats, hamsters, rabbits, cats, dogs, cows, sheep, and monkeys.
- compound (I) can be administered orally or parenterally as it is or in combination with a pharmaceutically acceptable carrier.
- Examples of dosage forms for oral administration of a preparation containing Compound (I) include tablets (including sugar-coated tablets and film-coated tablets), pills, granules, powders, capsules (soft capsules, microcapsules). ), Syrups, emulsions, suspensions, and dosage forms for parenteral administration include, for example, injections, infusions, drops, and suppositories. Also, combined with an appropriate base (eg, butyric acid polymer, glycolic acid polymer, butyric acid-glycolic acid copolymer, butyric acid polymer / glycolic acid polymer mixture, polyglycerol fatty acid ester) It is also effective to make a sustained-release preparation.
- an appropriate base eg, butyric acid polymer, glycolic acid polymer, butyric acid-glycolic acid copolymer, butyric acid polymer / glycolic acid polymer mixture, polyglycerol fatty acid ester
- Preparation of the above-mentioned dosage form containing Compound (I) can be carried out according to a known production method generally used in the pharmaceutical field. In this case, if necessary, it is produced by containing excipients, binders, lubricants, disintegrating agents, sweeteners, surfactants, suspending agents, emulsifiers and the like that are generally used in the pharmaceutical field. be able to.
- Preparation of tablets containing compound (I) can be carried out by containing excipients, binders, disintegrants, lubricants, etc., and pills and granules are prepared by excipients, binders It can be carried out by adding a disintegrant or the like. Powders and capsules are prepared with excipients, syrups are prepared with sweeteners, and emulsions or suspensions are added with surfactants, suspending agents, emulsifiers and the like. be able to.
- excipient examples include lactose, glucose, starch, sucrose, microcrystalline cellulose, licorice powder, mannitol, sodium bicarbonate, calcium phosphate, and calcium sulfate.
- binder examples include starch paste, gum arabic, gelatin, tragacanth, carboxymethylcellulose, sodium alginate, and glycerin.
- disintegrant examples include starch and calcium carbonate.
- Examples of the lubricant include magnesium stearate, stearic acid, calcium stearate, and purified talc.
- sweetening agent examples include glucose, fructose, invert sugar, sorbitol, xylitol, glycerin, and simple syrup.
- surfactant examples include sodium lauryl sulfate, polysorbate 80, sorbitan monofatty acid ester, and polyoxyl 40 stearate.
- suspending agent examples include gum arabic, sodium alginate, sodium carboxymethyl cellulose, methyl cellulose, and bentonite.
- emulsifier examples include gum arabic, tragacanth, gelatin, and polysorbate 80.
- the daily dose of the above preparation varies depending on the patient's condition and body weight, the type of compound, the route of administration, etc. For example, when administered orally, it is 1 mg to 1000 mg for an adult (body weight of about 60 kg). In the range, it is preferably administered in 1 to 3 divided doses. In the case of parenteral administration, in the case of an injection, it is preferably administered by intravenous injection in the range of 0.01 to 100 mg / kg body weight.
- the therapeutic agent or prophylactic agent for Alzheimer's disease of the present invention may be used in combination with another therapeutic agent or prophylactic agent for Alzheimer's disease or a therapeutic agent or prophylactic agent for non-cognitive symptoms in Alzheimer's disease patients.
- Other therapeutic agents or preventive agents for Alzheimer's disease include, for example, antagonists of cholinesterases such as donepezil, rivastigmine, galantamine, tacrine, and NMDA receptors such as memantine. Examples include drugs.
- Examples of the therapeutic or preventive agent for non-cognitive symptoms in Alzheimer's disease patients include amitriptyline, fluoxetine, clomipramine, citalopram, fluvoxamine, and fluvoxamine.
- Antidepressants such as Maprotiline, Moclobemide, Paroxetine, Mirtazapine, Chlorprozazine, Trifluoperazine, Trifluoperazine eridol), thiothixene, olanzapine, risperidone, clozapine, quetiapine, aripiprazole, eiprazol Examples thereof include carbamazepine (Carbamazepine), valproate (Valproate), trazodone (Trazodone), an antidepressant such as divalproex, and a benzodiazepine-based drug such as lorazepam (Lorazepam).
- phosphate buffer 50 mM
- the learning / memory function of the test rat was evaluated by the Morris water maze test. Specifically, a circular pool having a diameter of 150 cm, a height of 45 cm, and a water depth of 30 cm was prepared, and a colorless and transparent platform having a diameter of 12 cm was installed approximately 1 cm below the water surface.
- the water temperature in the circular pool is set to 23 ⁇ 1 ° C, the room where the circular pool is prepared is indirect lighting, and around the circular pool are placed visual clues for the test rat (calendar, desk, PC) did. During the test period, the arrangement of these visual cues was not changed at all.
- the swimming time (hereinafter referred to as “Escape latency”) until the test rat at an arbitrary start position in the circular pool reaches the platform was measured by recording the movement trajectory of the test rat with a video image behavior analyzer.
- the day when the basal ganglia destruction treatment (hereinafter, destruction treatment) was performed was regarded as day 0, and on the ninth day after the destruction treatment, the test rats were allowed to swim in a circular pool without a platform and acclimatized to water.
- the measurement of the escape latency was carried out 10 to 12 days after the destruction treatment, and 3 trials per day were performed at 30 minute intervals. The starting position was changed from trial to trial, but all platforms were placed at the same location in the trial. In addition, the test rats that could not reach the platform after 90 seconds from the start were allowed to stay on the platform for 30 seconds after swimming. In addition, the average value of Escape latency of 3 trials was made into Escape latency of each test rat.
- compound 3 contained in compound (I) was used.
- donepezil hydrochloride (Aricept (registered trademark) D tablet 3 mg (Eisai Co., Ltd.) was used after being ground) was used.
- Compound 3 and donepezil hydrochloride are suspended in a 0.5% methylcellulose solution (hereinafter referred to as 0.5% MC) to a concentration of 6 mg / mL and 0.1 mg / mL, respectively, and 5 mL / kg body weight is administered. Orally administered by volume.
- Compound 3 and donepezil hydrochloride were administered to the test rats according to the following schedule.
- 0.5% MC was administered to rats in the sham surgery group, solvent administration group, and compound 3 administration group 60 minutes before the start of the first trial of the Morris water maze on each day.
- Donepezil hydrochloride was administered to rats in the group administered with donepezil hydrochloride.
- 0.5% MC was administered to rats in the sham surgery group, the solvent administration group, and the donepezil hydrochloride administration group, and the compound 3 administration group Rats received Compound 3.
- the horizontal axis shows the Escape latency measurement date by the Morris water maze.
- the first day in the figure is the 10th day after the destruction treatment, the second day is the 11th day after the destruction treatment, and the third day is the 12th day after the destruction treatment. Equivalent to.
- the *, **, and $$ marks in the figure are statistically significant in comparison with the sham operation group (“Sham operation” group in the figure) (*: p ⁇ 0.05, **: p ⁇ 0.01 (Student's t-test), $$: p ⁇ 0.01 (Aspin-Welch test)). ## and!
- Cholinesterase inhibitors such as donepezil exhibit Alzheimer's disease therapeutic effects by suppressing the degradation of acetylcholine, which is decreased in the brain of Alzheimer's disease patients, and increasing the amount of acetylcholine in the brain. This mechanism of action is also apparent from the fact that in the Morris water maze test, the Escape latency of the rats in the donepezil hydrochloride administration group administered with donepezil hydrochloride immediately before the trial was shortened to the same extent as in the sham operation group.
- cholinesterase inhibitors can transiently improve the symptoms of Alzheimer's disease, they are thought to have no effect of inhibiting or delaying the progression of Alzheimer's disease (Blennow et al., Lancet, 2006, 368, p.387). It is also known that the effect of improving symptoms of Alzheimer's disease gradually attenuates when cholinesterase inhibitors are taken for a long time (Bullock et al., Int. J. Clin. Prac., 2005, Vol. 59). , P. 817).
- Compound 3 has a different administration schedule from that of donepezil hydrochloride and was administered orally once a day from day 0 after the destruction treatment, but was administered immediately before the trial on the 10th to 12th days after the destruction treatment. Absent. For this reason, at the time of trial, it is considered that compound 3 does not exist in the body of the rat in the compound 3 administration group.
- the action mechanism of the compound 3 is different from that of donepezil hydrochloride, and the compound 3 has Alzheimer's disease. It is thought that it has a remarkable effect of inhibiting or delaying the progression. That is, the results of the above Morris water maze test indicate that the compound (I) having a cyclohexane skeleton can sufficiently maintain the treatment or prevention effect of Alzheimer's disease even after long-term administration.
- the mouse partial sciatic nerve ligation model was prepared according to the method of Seltzer et al. (Malberg et al., Pain, 1998, Vol. 76, p. 215-222). ICR male male, 5 weeks old, anesthetized with sodium pentobarbital (70 mg / kg, ip), exposed sciatic nerve of right hind leg thigh, 8-0 silk thread under microscope (Natsume Seisakusho) A group in which the sciatic nerve was triple-ligated only half a circle using the ligation group was defined as a ligation group, and a group in which only the sciatic nerve was exposed and not ligated was defined as a sham operation group.
- neuropathic pain (hereinafter referred to as von Frey test) was performed by acclimating a mouse for at least 1 hour in a measurement acrylic cage (Natsume Seisakusho) installed on a wire mesh, and then applying a filament (0.16 g pressure) Using North Coast Medical, Inc.
- the test compound was orally administered 7 days after the sciatic nerve ligation operation.
- the von Frey test was conducted before oral administration of the test compound, and the animals in the ligation group were divided into a solvent group and a test compound administration group so that the total of the total scores was uniform.
- a von Frey test was performed for each of the sham surgery group, the solvent group, and the test compound administration group 1 hour, 2 hours, and 3 hours after oral administration of the solvent or the test compound, and the value was used as an index of the analgesic effect.
- DMSO dimethyl sulfoxide
- Tween 80 distilled water (1: 1: 8)
- 27% HP- ⁇ - CD 27% hydroxypropyl- ⁇ -cyclodextrin
- 0.5% MC 0.5%
- Table 3 shows the results 1 hour after oral administration of the solvent and the test compound.
- a statistical treatment was performed by t-test (corrected by Dunnett) with no correspondence between multiple groups, with the solvent group at each measurement time as a control.
- Score improvement rate 100 ⁇ (average value of total score of test compound administration group ⁇ average value of total score of sham operation group) / (average value of total score of solvent group ⁇ average value of total score of sham operation group) ⁇ Calculated as 100.
- the solvent name in parentheses shown in the NMR data indicates the solvent used for the measurement.
- the 400 MHz NMR spectrum was measured using a JNM-AL400 type nuclear magnetic resonance apparatus manufactured by JEOL. Chemical shifts are expressed in terms of ⁇ (unit: ppm) based on tetramethylsilane, and signals are represented by s (single line), d (double line), t (triple line), q (quadruple line), quint ( Quintet), sept (sevent), m (multiple line), br (wide), dd (double double line), dt (double triple line), ddd (double double line), It was represented by dq (double quadruple line), td (triple double line), and tt (triple triple line).
- the IR spectrum was measured using FT / IR-410 manufactured by JASCO, and the ESI-MS spectrum was measured using Micromass ZQ2K manufactured by Waters or 1200LC / MSD manufactured by Agilent Technology. All solvents were commercially available. For flash chromatography, YFLC W-prep2XY manufactured by Yamazen Co., Ltd. was used.
- Tetra n-butylammonium fluoride (TBAF, 1M-tetrahydrofuran solution) (3.29 mL, 3.29 mmol) was added to the reaction mixture, and the mixture was stirred at room temperature for 1 hour, and then poured into 1M hydrochloric acid. The reaction solution was extracted with diethyl ether. The organic layer was washed with brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by flash chromatography (silica gel, n-hexane / ethyl acetate) to give compound 10 (410 mg, 0.92 mmol, 56%) as a white solid.
- Compound 11 is t-4-fluoro-4- (1- (4-methoxyphenyl) -5- (p-tolyl) -1H-pyrazol-3-yl) -cyclohexane-r-1-ol. was synthesized by the following procedure.
- the reaction mixture was concentrated under reduced pressure, dissolved in tetrahydrofuran (3.0 mL), distilled water (0.2 mL) and 1.0 M-tetrabutylammonium fluoride / tetrahydrofuran solution (1.02 mL, 1.02 mmol) were added, and room temperature was added. For 30 minutes. Distilled water was added to the reaction solution, extracted with ethyl acetate, and washed with brine. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure.
- Compound 58 is ethyl 4-hydroxy-4- (1- (4-methoxyphenyl) -5- (p-tolyl) -1H-pyrazol-3-yl) -cis-cyclohexanecarboxylate was synthesized by the following procedure.
- Compound 60 is cyclohexyl 4-hydroxy-4- (1- (4-methoxyphenyl) -5- (p-tolyl) -1H-pyrazol-3-yl) -cis-cyclohexyl carbonate. was synthesized by the following procedure.
- Compound 64 is cyclohexyl (4-hydroxy-4- (1- (4-methoxyphenyl) -5- (p-tolyl) -1H-pyrazol-3-yl) -cis-cyclohexyloxy) ethyl carbonate. was synthesized by the following procedure.
- decan-8-ol (intermediate 1) (15.0 g, 82.3 mmol) in tetrahydrofuran (165 mL) was added 2.77 Mn-butyllithium ( n-hexane solution, 62.4 mL, 172.9 mmol) was added dropwise at ⁇ 72 ° C. for 25 minutes and stirred at the same temperature for 30 minutes, and then p-tolualdehyde (10.2 mL, 86.4 mmol) was added at ⁇ 72 ° C. For 5 minutes and stirred at the same temperature for 30 minutes.
- reaction solution was warmed to room temperature and then poured into a saturated aqueous ammonium chloride solution.
- the reaction solution was extracted with ethyl acetate.
- the organic layer was washed with brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure.
- the residue was purified by flash chromatography (silica gel, n-hexane / ethyl acetate) to give Intermediate 3 (17.7 g, 58.5 mmol, 71%) as amorphous.
- decan-8-ol (intermediate 1) (5.02 g, 27.6 mmol) in tetrahydrofuran (100 mL) was added 2.63 M-n-butyllithium ( n-hexane solution, 22.0 mL, 57.9 mmol) was added dropwise at ⁇ 72 ° C. for 15 minutes, and the mixture was stirred at the same temperature for 60 minutes, and then 4-methoxyaldehyde (3.52 mL, 28.9 mmol) was added at ⁇ 72 ° C. For 10 minutes and stirred at the same temperature for 60 minutes.
- reaction solution was warmed to room temperature and then poured into a saturated aqueous ammonium chloride solution.
- the reaction solution was extracted with ethyl acetate.
- the organic layer was washed with brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure.
- the residue was purified by flash chromatography (silica gel, n-hexane / ethyl acetate) to give Intermediate 4 (7.46 g, 23.4 mmol, 85%) as amorphous.
- decan-8-ol (intermediate 1) (5.03 g, 27.6 mmol) in tetrahydrofuran (100 mL) was added 2.63 M-n-butyllithium ( n-hexane solution, 22.1 mL, 57.9 mmol) was added dropwise at ⁇ 72 ° C. for 15 minutes, and the mixture was stirred at the same temperature for 60 minutes, and then 4-chlorobenzaldehyde (4.06 g, 28.9 mmol) was added at ⁇ 72 ° C. For 10 minutes and stirred at the same temperature for 60 minutes.
- reaction solution was warmed to room temperature and then poured into a saturated aqueous ammonium chloride solution.
- the reaction solution was extracted with ethyl acetate.
- the organic layer was washed with brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure.
- the residue was purified by flash chromatography (silica gel, n-hexane / ethyl acetate) to give Intermediate 5 (8.13 g, 25.2 mmol, 91%) as amorphous.
- decan-8-ol (intermediate 1) (592 mg, 3.25 mmol) in tetrahydrofuran (6 mL), 2.63 Mn-butyllithium (n- A hexane solution, 2.6 mL, 6.82 mmol) was added dropwise at ⁇ 78 ° C. for 5 minutes, and the mixture was stirred at the same temperature for 30 minutes, and then N-methoxy-N-methyl-6-methylnicotinamide (614.5 mg, 3 .41 mmol) in tetrahydrofuran (5 ml) was added dropwise at ⁇ 78 ° C.
- Triethylamine (5.87 mL, 42.1 mmol) was added dropwise to a solution of 4-methoxyphenylhydrazine hydrochloride (7.35 g, 42.1 mmol) in ethanol (76.6 mL), and the mixture was stirred at room temperature for 30 minutes.
- 3- (8-hydroxy-1,4-dioxaspiro [4.5] decan-8-yl) -1- (p-tolyl) -2-propyn-1-one (intermediate 9) (11. 5 g, 38.3 mmol) in ethanol (76.6 mL) was added dropwise and stirred at room temperature for 15 hours, and then the reaction solution was concentrated under reduced pressure.
- Triethylamine (286 ⁇ L, 2.06 mmol) was added dropwise to a solution of 4-methoxyphenylhydrazine hydrochloride (359 mg, 2.06 mmol) in ethanol (4 mL), and the mixture was stirred at room temperature for 30 minutes.
- To the reaction solution 3- (8-hydroxy-1,4-dioxaspiro [4.5] decan-8-yl) -1- (6-methylpyridin-3-yl) -2-propyn-1-one (intermediate) 10)
- a solution of 563.7 mg, 1.87 mmol) in ethanol (5.4 mL) was added dropwise, and the mixture was stirred at room temperature for 22 hours, and then the reaction solution was concentrated under reduced pressure.
- Triethylamine (0.730 mL, 5.24 mmol) was added dropwise to a solution of 4-methoxyphenylhydrazine hydrochloride (457 mg, 2.62 mmol) in ethanol (4.4 mL), and the mixture was stirred at room temperature for 30 minutes.
- 1- (4-chlorophenyl) -3- (8-hydroxy-1,4-dioxaspiro [4.5] decan-8-yl) -2-propyn-1-one (intermediate 12) 700 mg, 2.18 mmol
- ethanol 4.4 mL
- Triethylamine (5.87 mL, 42.1 mmol) was added dropwise to a solution of 4-chlorophenylhydrazine hydrochloride (418 mg, 2.33 mmol) in ethanol (4.8 mL), and the mixture was stirred at room temperature for 30 minutes.
- 3- (8-hydroxy-1,4-dioxaspiro [4.5] decan-8-yl) -1- (p-tolyl) -2-propyn-1-one (intermediate 9) (698 mg, A solution of 2.32 mmol) in ethanol (4.7 mL) was added dropwise and stirred at room temperature for 14 hours, and then the reaction solution was concentrated under reduced pressure. Water was added to the residue and extracted with ethyl acetate.
- Triethylamine (0.447 mL, 3.20 mmol) was added dropwise to a solution of 4-methoxyphenylhydrazine hydrochloride (280 mg, 1.60 mmol) in ethanol (2.7 mL), and the mixture was stirred at room temperature for 30 minutes.
- 3- (8- (benzyloxymethyl) -1,4-dioxaspiro [4.5] decan-8-yl) -1- (p-tolyl) propin-1-one (intermediate 49) (540 mg) 1.33 mmol) in ethanol (2.7 mL) was added dropwise and stirred at room temperature for 14 hours, and then the reaction solution was concentrated under reduced pressure.
- 1,4-Cyclohexanedione monoethylene ketal (524 mg, 3.36 mmol) was added to the reaction solution, and the temperature was gradually raised to room temperature while stirring.
- the reaction mixture was acidified with 1M hydrochloric acid and extracted with ethyl acetate.
- the organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure.
- the residue was purified by flash chromatography (silica gel, n-hexane / ethyl acetate) to obtain Intermediate 52 (844 mg, 1.92 mmol, 60%) as a pale yellow amorphous.
- decan-8-ol ( 6M-hydrochloric acid (1.2 mL) was added to a solution of intermediate 19) (128.8 mg, 0.30 mmol) in tetrahydrofuran (0.6 mL), and the mixture was stirred at room temperature for 3 hours. The reaction mixture was ice-cooled, 50% aqueous sodium hydroxide solution was added dropwise at 0 ° C. until basic, and the mixture was extracted with ethyl acetate.
- decan-8-ol (Intermediate 22) (931 mg , 2.19 mmol) in tetrahydrofuran (5.5 mL) was added 6M-hydrochloric acid (11 mL), and the mixture was stirred at room temperature for 15 hours.
- the reaction solution was poured into a saturated aqueous sodium hydrogen carbonate solution to make it basic, and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure.
- decan-8-ol (intermediate 52) (781 mg, 1.78 mmol) in tetrahydrofuran 6M hydrochloric acid (9.0 mL) was added to the (4.5 mL) solution at 0 ° C., and the mixture was stirred at room temperature for 2 hours. The reaction mixture was cooled to 0 ° C., 10% aqueous sodium hydroxide and saturated aqueous sodium hydrogen carbonate were added to make it alkaline, and the mixture was extracted with ethyl acetate.
- decan-8-ol (intermediate 56) (469 mg, 1 0.07 mmol) in tetrahydrofuran (5.4 mL) was added 6M-hydrochloric acid (5.4 mL) at 0 ° C., and the mixture was stirred at room temperature for 14 hours.
- the reaction solution was poured into a saturated aqueous sodium hydrogen carbonate solution to make it basic, and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure.
- the cyclohexane derivative of the present invention or a pharmacologically acceptable salt thereof or a prodrug thereof can be used as a medicament containing them as an active ingredient, particularly as a therapeutic or prophylactic agent for Alzheimer's disease.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Description
[式中、Aは、一般式(IIa)又は(IIb)で表される置換基であり、
で示される化合物又はその薬理学的に許容される塩若しくはそのプロドラッグであることを特徴としている。
化合物(Ia)又は化合物(Ib)のアルキル化反応は、一般に、化合物(Ia)又は化合物(Ib)を塩基存在下の溶媒中でハロゲン化アルキルと反応させることにより行われ、反応を阻害しない溶媒が適宜選択される。反応を阻害しない溶媒としては、例えば、テトラヒドロフラン、1,4-ジオキサン、エチレングリコールジメチルエーテル等のエーテル類、アセトン、アセトニトリル又はN,N-ジメチルホルムアミドが挙げられるが、これらの混合溶媒を用いてもよい。
化合物(Ia)又は化合物(Ib)のアシル化反応は、一般に、化合物(Ia)又は化合物(Ib)を塩基存在下の溶媒中で酸ハロゲン化物又は酸無水物等のアシル化剤と反応させることにより行われ、反応を阻害しない溶媒が適宜選択される。反応を阻害しない溶媒としては、例えば、ジクロロメタン、クロロホルム、四塩化炭素、1,2-ジクロロエタン等のハロゲン化炭化水素、テトラヒドロフラン、1,2-ジメトキシエタン、1,4-ジオキサン等のエーテル類が挙げられるが、これらの混合溶媒を用いてもよい。
化合物(Ig)のフッ素化反応は、一般に、溶媒中で化合物(Ig)をフッ素化剤と反応させることにより行われ、反応を阻害しない溶媒が適宜選択される。反応を阻害しない溶媒としては、例えば、オクタン、ヘキサン、ベンゼン、トルエン等の炭化水素類、ジクロロメタン、クロロホルム、四塩化炭素、1,2-ジクロロエタン等のハロゲン化炭化水素、テトラヒドロフラン、1,2-ジメトキシエタン、1,4-ジオキサン等のエーテル類又はアセトニトリル等のアルキルニトリル類が挙げられるが、これらの混合溶媒を用いてもよい。
化合物(Ii)のフッ素化反応は、一般に、化合物(Ii)を溶媒中でフッ素化剤と反応させることにより行われ、反応を阻害しない溶媒が適宜選択される。反応を阻害しない溶媒としては、例えば、オクタン、ヘキサン、ベンゼン、トルエン等の炭化水素類、ジクロロメタン、クロロホルム、四塩化炭素、1,2-ジクロロエタン等のハロゲン化炭化水素、テトラヒドロフラン、1,2-ジメトキシエタン、1,4-ジオキサン等のエーテル類又はアセトニトリル等のアルキルニトリル類が挙げられるが、又はこれらの混合溶媒を用いてもよい。
化合物(Ii)の還元反応は、一般に、化合物(Ii)を溶媒中で還元剤と反応させることにより行われ、反応を阻害しない溶媒が適宜選択される。反応を阻害しない溶媒としては、例えば、オクタン、ヘキサン、ベンゼン、トルエン等の炭化水素類、テトラヒドロフラン、1,4-ジオキサン、エチレングリコールジメチルエーテル、ジエチルエーテル等のエーテル類、メタノール、エタノール、イソプロピルアルコール等のアルコール類が挙げられるが、これらの混合溶媒を用いてもよい。
トリフルオロメチル化剤としては、例えば、(トリフルオロメチル)トリメチルシラン等の有機珪素化合物が挙げられる。有機珪素化合物を用いるトリフルオロメチル化反応は、公知文献(Journal of the American Chemical Society、1989年、39巻、p.393~395)に記載の方法又はこれに準ずる方法に従って行うことができる。
化合物(Ii)のWittig反応は、一般に、化合物(Ii)を塩基存在下の溶媒中でWittig試薬と反応させることにより行われ、反応を阻害しない溶媒が適宜選択される。反応を阻害しない溶媒としては、例えば、オクタン、ヘキサン、ベンゼン、トルエン等の炭化水素類、テトラヒドロフラン、1,4-ジオキサン、エチレングリコールジメチルエーテル、ジエチルエーテル等のエーテル類が挙げられるが、これらの混合溶媒を用いてもよい。
化合物(SI)の酸化反応に用いる酸化剤としては、例えば、酸化クロム(VI)-酢酸、Jones試薬又は亜塩素酸ナトリウム等が挙げられる。上記の酸化反応は、当業者に自明の方法に従って行うことができる。
化合物(Ip)の脱保護反応は公知文献(PROTECTIVE GROUPS IN ORGANIC SYNTHESIS(WILEY-INTERSCIENCE))に記載の方法又はこれに準ずる方法に従って行うことができる。
化合物(IIIa)の塩素化反応は、一般に、化合物(IIIa)を溶媒中で塩素化剤と反応させることにより行われ、反応を阻害しない溶媒が適宜選択される。反応を阻害しない溶媒としては、例えば、ジクロロメタン、クロロホルム、四塩化炭素、1,2-ジクロロエタン等のハロゲン化炭化水素、アセトニトリル又は酢酸エチルが挙げられるが、これらの混合溶媒を用いてもよい。
化合物(LII)と化合物(SII)との環化反応は、一般に、適宜選択した反応を阻害しない溶媒中で行われる。反応を阻害しない溶媒としては、例えば、メタノール、エタノール、イソプロピルアルコール等のアルコール類、ジクロロメタン、クロロホルム、四塩化炭素、1,2-ジクロロエタン等のハロゲン化炭化水素、テトラヒドロフラン、1,2-ジメトキシエタン、1,4-ジオキサン等のエーテル類、ベンゼン、トルエン、酢酸又は水が挙げられるが、これらの混合溶媒を用いてもよい。
化合物(SIII)の脱プロトン化反応及び酸化反応は、一般に、化合物(SIII)を脱水溶媒中で塩基及び酸化剤と反応させることにより行われ、反応を阻害しない溶媒が適宜選択される。反応を阻害しない溶媒としては、例えば、オクタン、ヘキサン、ヘプタン等の炭化水素類、テトラヒドロフラン、1,4-ジオキサン、エチレングリコールジメチルエーテル、ジエチルエーテル等のエーテル類が挙げられるが、これらの混合溶媒を用いてもよい。
化合物(LIV)と化合物(LV)との反応は、一般に、塩基存在下の脱水溶媒中で行われ、反応を阻害しない溶媒が適宜選択される。反応を阻害しない溶媒としては、例えば、オクタン、ヘキサン、ベンゼン、トルエン等の炭化水素類、テトラヒドロフラン、1,4-ジオキサン、エチレングリコールジメチルエーテル、ジエチルエーテル等のエーテル類が挙げられるが、これらの混合溶媒を用いてもよい。
上記の加溶媒分解反応は、一般に、塩基存在下の溶媒中で行われ、反応を阻害しない溶媒が適宜選択される。反応を阻害しない溶媒としては、例えば、メタノール、エタノール等のアルコール類又は水が挙げられるが、これらの混合溶媒を用いてもよい。
化合物(VI)と化合物(LVI)又は化合物(LVII)との反応は、一般に、塩基存在下の脱水溶媒中で行われ、反応を阻害しない溶媒が適宜選択される。反応を阻害しない溶媒としては、例えば、オクタン、ヘキサン、ベンゼン、トルエン等の炭化水素類、テトラヒドロフラン、1,4-ジオキサン、エチレングリコールジメチルエーテル、ジエチルエーテル等のエーテル類が挙げられるが、これらの混合溶媒を用いてもよい。
化合物(VII)の酸化反応は、一般に、化合物(VII)を溶媒中で酸化剤と反応させることにより行われ、反応を阻害しない溶媒が適宜選択される。反応を阻害しない溶媒としては、例えば、オクタン、ヘキサン、ベンゼン、トルエン等の炭化水素類、ジクロロメタン、クロロホルム、四塩化炭素、1,2-ジクロロエタン等のハロゲン化炭化水素、テトラヒドロフラン、1,2-ジメトキシエタン、1,4-ジオキサン等のエーテル類又はアセトニトリル等のアルキルニトリル類、トリフルオロ酢酸、ピリジン、アセトン等が挙げられるが、これらの混合溶媒を用いてもよい。
化合物(VIII)と化合物(LVIII)との反応は、一般に、塩基存在下の脱水溶媒中で行われ、反応を阻害しない溶媒が適宜選択される。反応を阻害しない溶媒としては、例えば、オクタン、ヘキサン、ベンゼン、トルエン等の炭化水素類、テトラヒドロフラン、1,4-ジオキサン、エチレングリコールジメチルエーテル、ジエチルエーテル等のエーテル類が挙げられるが、これらの混合溶媒を用いてもよい。
化合物(IX)の還元反応は、一般に、化合物(IX)を溶媒中で還元剤と反応させることにより行われ、反応を阻害しない溶媒が適宜選択される。反応を阻害しない溶媒としてはオクタン、ヘキサン、ベンゼン、トルエン等の炭化水素類、テトラヒドロフラン、1,4-ジオキサン、エチレングリコールジメチルエーテル、ジエチルエーテル等のエーテル類又はメタノール、エタノール、イソプロピルアルコール等のアルコール類が挙げられるが、これらの混合溶媒を用いてもよい。
化合物(X)の酸化反応は、一般に、化合物(X)を溶媒中で酸化剤と反応させることにより行われ、反応を阻害しない溶媒が適宜選択される。反応を阻害しない溶媒としては、例えば、トリフルオロ酢酸、ピリジン、アセトン、オクタン、ヘキサン、ベンゼン、トルエン等の炭化水素類、ジクロロメタン、クロロホルム、四塩化炭素、1,2-ジクロロエタン等のハロゲン化炭化水素、テトラヒドロフラン、1,2-ジメトキシエタン、1,4-ジオキサン等のエーテル類又はアセトニトリル等のアルキルニトリル類が挙げられるが、これらの混合溶媒を用いてもよい。
化合物(XII)は化合物(XI)のアルキンへの変換によって得られる。上記の変換反応に用いる試薬としては、例えば、ジメチル-1-ジアゾ-2-オキソプロピルホスホナートが挙げられる。上記の変換反応は公知文献(Tetrahedron Letters、2006年、47巻、p.1729~1731)に記載の方法又はこれに準ずる方法に従って行うことができる。
化合物(XII)の求核付加反応は、一般に、塩基存在下の脱水溶媒中で行われ、反応を阻害しない溶媒が適宜選択される。反応を阻害しない溶媒としては、例えば、オクタン、ヘキサン、ベンゼン、トルエン等の炭化水素類、テトラヒドロフラン、1,4-ジオキサン、エチレングリコールジメチルエーテル、ジエチルエーテル等のエーテル類が挙げられるが、これらの混合溶媒を用いてもよい。
化合物(XIII)の酸化反応は、一般に、化合物(XIII)を溶媒中で酸化剤と反応させることにより行われ、反応を阻害しない溶媒が適宜選択される。反応を阻害しない溶媒としては、例えば、トリフルオロ酢酸、ピリジン、アセトン、オクタン、ヘキサン、ベンゼン、トルエン等の炭化水素類、ジクロロメタン、クロロホルム、四塩化炭素、1,2-ジクロロエタン等のハロゲン化炭化水素、テトラヒドロフラン、1,2-ジメトキシエタン、1,4-ジオキサン等のエーテル類又はアセトニトリル等のアルキルニトリル類が挙げられるが、これらの混合溶媒を用いてもよい。
化合物(XIV)のアルキル化反応は、一般に、化合物(XIV)を塩基存在下の溶媒中でハロゲン化アルキルと反応することにより行われ、反応を阻害しない溶媒が適宜選択される。反応を阻害しない溶媒としては、テトラヒドロフラン、1,4-ジオキサン、エチレングリコールジメチルエーテル等のエーテル類、アセトン、アセトニトリル又はN,N-ジメチルホルムアミドが挙げられるが、これらの混合溶媒を用いてもよい。
化合物(XVI)は、例えば、塩化チオニル又はオキサリルクロリド等を用いる当業者に自明の方法に従って、化合物(XIV)から合成することができる。
化合物(XVI)による化合物(LXI)のアシル化反応は、一般に、塩基存在下の溶媒中で行われ、反応を阻害しない溶媒が適宜選択される。反応を阻害しない溶媒としては、例えば、ジクロロメタン、クロロホルム、四塩化炭素、1,2-ジクロロエタン等のハロゲン化炭化水素、テトラヒドロフラン、1,2-ジメトキシエタン、1,4-ジオキサン等のエーテル類が挙げられるが、これらの混合溶媒を用いてもよい。
化合物(XV)の環化反応は、一般に、アンモニウム塩存在下の溶媒中で行われ、反応を阻害しない溶媒が適宜選択される。反応を阻害しない溶媒としては、例えば、酢酸又はギ酸が挙げられるが、これらの混合溶媒を用いてもよい。
化合物(XIV)のアミド化反応は、一般に、塩基存在下の溶媒中でクロロギ酸エステル等を用いて混合酸無水物を形成した後、アンモニア水を反応させることにより行われ、反応を阻害しない溶媒が適宜選択される。反応を阻害しない溶媒としては、例えば、テトラヒドロフラン、1,4-ジオキサン、エチレングリコールジメチルエーテル等のエーテル類、ジクロロメタン、クロロホルム等のハロゲン化炭化水素又はN,N-ジメチルホルムアミドが挙げられるが、これらの混合溶媒を用いてもよい。
化合物(XVII)のチオアミド化反応は、一般に、化合物(XVII)を溶媒中でローソン試薬又は五硫化リン等の市販の試薬と反応させることにより行われ、反応を阻害しない溶媒が適宜選択される。反応を阻害しない溶媒としては、例えば、ベンゼン、トルエン等の飽和炭化水素、ジクロロメタン、クロロホルム等のハロゲン溶媒又はテトラヒドロフラン、1,4-ジオキサン等のエーテル類が挙げられるが、これらの混合溶媒を用いてもよい。
化合物(XVIII)の環化反応は、一般に、適宜選択した反応を阻害しない溶媒中で行われる。反応を阻害しない溶媒としては、例えば、メタノール、エタノール等のアルコール類、テトラヒドロフラン、1,4-ジオキサン等のエーテル類又はアセトニトリルが挙げられるが、これらの混合溶媒を用いてもよい。
試験には、7週齢のWistar系雄性ラットを1群10例で用いた。麻酔下のラットを脳定位固定装置に固定し、頭蓋骨を露出させてBregmaより後方1.4mm、正中線の左右2.8mmの位置2カ所に小骨窓を開けた。露出した硬膜より腹位7.6mmの大脳基底核にカテーテルを挿入し、5μgのイボテン酸を0.5μLのリン酸緩衝液(50mM)に溶かしたイボテン酸溶液を5分間かけて注入して大脳基底核を破壊処置し、アルツハイマー病モデルラットを作製した。なお、偽手術群のラットには、イボテン酸溶液に代えて0.5μLのリン酸緩衝液(50mM)を注入した。大脳皮質に投射しているアセチルコリン神経の起始核であって、学習・記憶機能にきわめて重要な役割を果たす大脳基底核を破壊されたラットは、大脳皮質でのアセチルコリン神経の機能異常によって学習・記憶機能に障害が生じることが知られている(Shinodaら、Behav. Brain Res.、1999年、第99巻、p.17)。
参考例として、神経因性疼痛を評価できるマウス坐骨神経部分結紮モデル(Seltzerモデル)を用い、化合物(I)の鎮痛効果を評価した。
スコア改善率=100-(被験化合物投与群の総スコアの平均値-偽手術群の総スコアの平均値)/(溶媒群の総スコアの平均値-偽手術群の総スコアの平均値)×100として算出した。
1H-NMR (400 MHz, CDCl3) δ: 1.31-1.42 (1H, m), 1.54-2.03 (9H, m), 2.33 (3H, s), 2.52 (1H, brs), 3.81 (3H, s), 6.40 (1H, s), 6.84 (2H, d, J=8.8 Hz), 7.09 (4H, s), 7.21 (2H, d, J=8.8 Hz).
化合物2として、1-(1-(4-メトキシフェニル)-5-(p-トリル)-1H-ピラゾール-3-イル)シクロヘキサン-トランス-1,4-ジオール
化合物2:1H-NMR (400 MHz, CDCl3) δ: 1.36 (1H, d, J=3.6 Hz), 1.64-1.72 (2H, m), 1.77-1.83 (2H, m), 2.04-2.12 (2H, m), 2.32-2.39 (5H, m), 2.56 (1H, s), 3.81 (3H, s), 4.03-4.06 (1H, m), 6.43 (1H, s), 6.85 (2H, d, J=8.8 Hz), 7.10 (4H, s), 7.21 (2H, d, J=8.8 Hz).
IR (KBr, cm-1): 3344, 2929, 2875, 1740, 1516, 1443, 1369, 1251, 1032, 1001, 832.
ESI-MS: m/z= 379 (M+H)+
Mp 151-153 ℃
Anal. Calcd for C23H26N2O3: C, 72.99; H, 6.92; N, 7.40. found: C, 72.97; H, 6.92; N, 7.34.
化合物3:1H-NMR (400 MHz, CDCl3) δ: 1.44 (1H, s), 1.81-1.99 (6H, m), 2.04-2.12 (2H, m), 2.33 (3H, s), 2.56 (1H, s), 3.70-3.77 (1H, m), 3.80 (3H, s), 6.37 (1H, s), 6.85 (2H, d, J=8.8 Hz), 7.09 (4H, s), 7.20 (2H, d, J=8.8 Hz).
IR (KBr, cm-1): 3303, 2918, 1517, 1442, 1366, 1248, 1063, 1026, 837, 807.
ESI-MS: m/z= 379 (M+H)+
Mp 164-166 ℃
Anal. Calcd for C23H26N2O3: C, 72.99; H, 6.92; N, 7.40. found: C, 72.87; H, 6.86; N, 7.22.
化合物5として、1-(1-(4-クロロフェニル)-5-(p-トリル)-1H-ピラゾール-3-イル)シクロヘキサン-トランス-1,4-ジオール
化合物5:1H-NMR (400 MHz, CDCl3) δ: 1.36 (1H, br), 1.65-1.72 (2H, m), 1.77-1.82 (2H, m), 2.04-2.11 (2H, m), 2.31-2.38 (2H, m), 2.36 (3H, s), 2.51 (1H, s), 4.03-4.08 (1H, m), 6.44 (1H, s), 7.10 (2H, d, J=8.8 Hz), 7.13 (2H, d, J=8.8 Hz), 7.22-7.30 (4H, m).
IR (KBr, cm-1): 3349, 2918, 1497, 1440, 1366, 1240, 1098, 1007, 969, 833, 810.
ESI-MS: m/z= 383 (M+H)+
化合物22:1H-NMR (400 MHz, CDCl3) δ: 1.45 (1H, br), 1.80-1.99 (6H, m), 2.03-2.07 (2H, m), 2.35 (3H, s), 2.51 (1H, s), 3.70-3.80 (1H, m), 6.39 (1H, s), 7.09 (2H, d, J=8.4 Hz), 7.13 (2H, d, J=8.4 Hz), 7.21-7.24 (2H, m), 7.27-7.31 (2H, m).
IR (KBr, cm-1): 3365, 2946, 1496, 1442, 1368, 1241, 1095, 1059, 1014, 970, 887.
ESI-MS: m/z= 365 (M-OH)+
化合物6として、1-(1,5-ビス(4-メトキシフェニル)-1H-ピラゾール-3-イル)シクロヘキサン-トランス-1,4-ジオール
化合物6:1H-NMR (400 MHz, CDCl3) δ: 1.33 (1H, d, J=3.4 Hz), 1.63-1.73 (2H, m), 1.75-1.84 (2H, m), 2.03-2.13 (2H, m), 2.30-2.39 (2H, m), 2.55 (1H, s), 3.80 (3H, s), 3.81 (3H, s), 4.02-4.08 (1H, m), 6.40 (1H, s), 6.82 (2H, d, J=8.8 Hz), 6.85 (2H, d, J=8.8 Hz), 7.14 (2H, d, J=8.8 Hz), 7.21 (2H, d, J=8.8 Hz).
IR (KBr, cm-1): 3379, 1613, 1517, 1503, 1251, 1180, 1032, 1001, 835.
ESI-MS: m/z= 395 (M+H)+
化合物8:1H-NMR (400 MHz, CDCl3) δ: 1.41 (1H, d, J=4.1 Hz), 1.79-2.55 (8H, m), 2.55 (1H, s), 3.69-3.78 (1H, m), 3.80 (3H, s), 3.81 (3H, s), 6.34 (1H, s), 6.81 (2H, d, J=8.8 Hz), 6.85 (2H, d, J=8.8 Hz), 7.13 (2H, d, J=8.8 Hz), 7.20 (2H, d, J=8.8 Hz).
IR (KBr, cm-1): 3385, 1613, 1517, 1503, 1250, 1064, 1031, 970, 835.
ESI-MS: m/z= 395 (M+H)+
化合物7として、1-(5-(4-クロロフェニル)-1-(4-メトキシフェニル)-1H-ピラゾール-3-イル)シクロヘキサン-トランス-1,4-ジオール
化合物7:1H-NMR (400 MHz, CDCl3) δ: 1.32 (1H, d, J=3.2 Hz), 1.63-1.73 (2H, m), 1.76-1.84 (2H, m), 2.03-2.12 (2H, m), 2.30-2.39 (2H, m), 2.50 (1H, s), 3.82 (3H, s), 4.02-4.09 (1H, m), 6.46 (1H, s), 6.84-6.87 (2H, m), 7.14 (2H, d, J=8.8 Hz), 7.19 (2H, d, J=8.8 Hz), 7.26-7.28 (2H, m).
ESI-MS: m/z= 399 (M+H)+
化合物21:1H-NMR (400 MHz, CDCl3) δ: 1.41 (1H, d, J=5.2 Hz), 1.82-2.09 (8H, m), 2.49 (1H, s), 3.70-3.78 (1H, s), 3.82 (3H, s), 6.41 (1H, s), 6.85-6.87 (2H, m), 7.13 (2H, d, J=8.4 Hz), 7.18 (2H, d, J=8.4 Hz), 7.25-7.27 (2H, m).
ESI-MS: m/z= 399 (M+H)+
1H-NMR (400MHz, CDCl3)δ: 1.45 (1H, s), 1.83-2.05 (6H, m), 2.21-2.23 (2H, m), 2.36 (3H, s), 3.04 (1H, s), 3.76-3.79 (4H, m), 6.79-6.83 (2H, m), 7.11-7.16 (6H, m).
ESI-MS: m/z= 395, 397 (M-OH)+
化合物10として、1-(1-(4-メトキシフェニル)-5-(p-トリル)-1H-ピラゾール-3-イル)-4-(トリフルオロメチル)シクロヘキサン-シス-1,4-ジオール
1H-NMR (400MHz, CDCl3) δ: 1.60 (1H, s), 1.87-2.02 (4H, m), 2.09-2.02 (2H, m), 2.34-2.40 (6H, m), 3.82 (3H, s), 6.47 (1H, s), 6.86 (2H, d, J=8.8 Hz), 7.08-7.11 (4H, m), 7.20 (2H, d, J=8.8 Hz).
IR (KBr, cm-1): 3402, 2954, 1517, 1463, 1305, 1250, 1249, 1179, 1121, 1056, 1024, 834.
ESI-MS: m/z= 447 (M+H)+
化合物11として、t-4-フルオロ-4-(1-(4-メトキシフェニル)-5-(p-トリル)-1H-ピラゾール-3-イル)-シクロヘキサン-r-1-オール
1H-NMR (400MHz, CDCl3)δ: 1.37 (1H, m), 1.72-1.77 (2H, m), 2.02-2.14 (4H, m), 2.34 (3H, s), 2.38-2.49 (2H, m), 3.81 (3H, s), 4.11 (1H, m), 6.52 (1H, m), 6.84 (2H, d, J=8.8 Hz), 7.22 (2H, d, J=8.8 Hz), 7.26 (4H, s).
ESI-MS: m/z= 381 (M+H)+
化合物12として、c-4-ヒドロキシ-4-(1-(4-メトキシフェニル)-5-(p-トリル)-1H-ピラゾール-3-イル)-シクロヘキサン-r-1-イル アセタート
1H-NMR (400 MHz, CDCl3) δ: 1.89-2.08 (11H, m), 2.34 (3H, s), 2.64 (1H, brs), 3.81 (3H, s), 4.80-4.88 (1H, m), 6.36 (1H, s), 6.85 (2H, d, J=8.8 Hz), 7.00 (4H, s), 7.20 (2H, d, J=8.8 Hz).
ESI-MS: m/z= 421 (M+H)+
1H-NMR (400 MHz, CDCl3) δ: 1.78-1.88 (2H, m), 1.90-1.99 (4H, m), 2.03-2.09 (2H, m), 2.33 (3H, s), 2.49 (1H, s), 3.24-3.32 (1H, m), 3.39 (3H, s), 3.81 (3H, s), 6.39 (1H, s), 6.85 (2H, d, J=8.8 Hz), 7.09 (4H, s), 7.20 (2H, d, J=8.8 Hz).
IR (KBr, cm-1): 3425, 2937, 1516, 1443, 1369, 1300, 1249, 1171, 1099, 1030, 968, 834, 801.
ESI-MS: m/z= 393 (M+H)+
化合物14として、4-(ヒドロキシメチル)-4-(1-(4-メトキシフェニル)-5-(p-トリル)-1H-ピラゾール-3-イル)-トランス-1,4-シクロヘキサノール
化合物14:1H-NMR (400 MHz, CDCl3) δ: 1.43 (1H, brs), 1.54-1.67 (2H, m), 1.83-1.91 (4H, m), 2.00-2.08 (2H, m), 2.34 (3H, s), 3.24-3.33 (1H, m), 3.78-3.86 (6H, m), 6.32 (1H, s), 6.84 (2H, d, J=8.8 Hz), 7.10 (4H, s), 7.19 (2H, d, J=8.8 Hz).
ESI-MS: m/z= 393 (M+H)+
化合物20:1H-NMR (400 MHz, CDCl3) δ: 1.39 (1H, d, J=4.8 Hz), 1.46-1.60 (4H, m), 1.85-1.95 (2H, m), 2.33-2.40 (5H, m), 2.71 (1H, t, J=6.4 Hz), 3.55 (2H, d, J=6.4 Hz), 3.71-3.83 (4H, m), 6.37 (1H, s), 6.85 (2H, d, J=8.8 Hz), 7.10 (4H, s), 7.20 (2H, d, J=8.8 Hz).
ESI-MS: m/z= 393 (M+H)+
化合物15として、1-(1-(4-メトキシフェニル)-5-(6-メチルピリジン-3-イル)-1H-ピラゾール-3-イル)シクロヘキサン-シス-1,4-ジオール
1H-NMR (400 MHz, CDCl3) δ: 1.59 (1H, brs), 1.81-2.00 (6H, m), 2.05-2.08 (2H, m), 2.55 (3H, s), 2.61 (1H, s), 3.71-3.78 (1H, m), 3.81 (3H, s), 6.46 (1H, s), 6.86 (2H, d, J=8.8 Hz), 7.06 (1H, d, J=8.0 Hz), 7.18 (2H, d, J=8.8 Hz), 7.32 (1H, dd, J=2.0, 8.0 Hz), 8.40 (1H, d, J=2.0 Hz).
IR (KBr, cm-1): 3444, 2933, 2858, 1516, 1249, 1067, 968, 839.
ESI-MS: m/z= 380 (M+H)+
化合物16として、4-ヒドロキシ-4-(1-(4-メトキシフェニル)-5-(p-トリル)-1H-ピラゾール-3-イル)-シス-シクロヘキサンカルボン酸
1H-NMR (400 MHz, CDCl3) δ: 1.87-2.11 (9H, m), 2.33 (3H, s), 2.40-2.43 (1H, m), 3.81 (3H, s), 6.38 (1H, s), 6.84 (2H, d, J=9.2 Hz), 7.09-7.09 (4H, m), 7.20 (2H, d, J=9.2 Hz).
IR (KBr, cm-1): 3523, 2928, 1706, 1517, 1252, 831.
ESI-MS: m/z= 407 (M+H)+
1H-NMR (400 MHz, CDCl3) δ: 2.01-2.31 (8H, m), 2.34 (3H, s), 2.77 (1H, s), 3.81 (3H, s), 6.37 (1H, s), 6.86 (2H, d, J=8.8 Hz), 7.10 (4H, s), 7.21 (2H, d, J=8.8 Hz).
ESI-MS: m/z= 399 (M+H)+
化合物41として、1-(4-(4-メトキシフェニル)-5-(p-トリル)チアゾール-2-イル)シクロヘキサン-トランス-1,4-ジオール
化合物41:1H-NMR (400 MHz, CDCl3) δ: 1.53-1.57 (1H, m), 1.76-1.87 (4H, m), 2.05-2.12 (2H, m), 2.35-2.42 (2H, m), 2.36 (3H, s), 3.15 (1H, br), 3.80 (3H, s), 4.10-4.14 (1H, m), 6.80-6.84 (2H, m), 7.13 (2H, d, J=8.0 Hz), 7.24 (2H, d, J=8.0 Hz), 7.45-7.49 (2H, m).
IR (KBr, cm-1): 3409, 2923, 1613, 1515, 1252, 1179, 1004, 815.
ESI-MS: m/z= 396 (M+H)+
化合物42:1H-NMR (400 MHz, CDCl3) δ: 1.48 (1H, d, J=4.8 Hz), 1.82-1.89 (2H, m), 1.95-2.01 (2H, m), 2.05-2.09 (4H, m), 2.36 (3H, s), 3.01 (1H, s), 3.76-3.82 (1H, m), 3.80 (3H, s), 6.80-6.83 (2H, m), 7.13 (2H, d, J=8.0 Hz), 7.22 (2H, d, J=8.0 Hz), 7.43-7.47 (2H, m).
IR (KBr, cm-1): 3418, 2938, 1611, 1515, 1249, 1177, 1058, 816.
ESI-MS: m/z= 396 (M+H)+
化合物43として、4-(4,5-ビス(4-メトキシフェニル)オキサゾール-2-イル)シクロヘキサン-シス-1,4-ジオール
化合物43:1H-NMR (400 MHz, CDCl3) δ: 1.49 (1H, brs), 1.78-2.13 (8H, m), 2.76 (1H, s), 3.72-3.78 (1H, m), 3.83 (6H, s), 6.89 (2H, d, J=8.8 Hz), 6.90 (2H, d, J=8.8 Hz), 7.49 (2H, d, J=8.8 Hz), 7.55 (2H, d, J=8.8 Hz).
IR (KBr,cm-1): 3364, 1615, 1599, 1520, 1500, 1302, 1252, 1176, 1069, 1053, 1028, 965, 833.
ESI-MS: m/z= 396 (M+H)+
化合物44:1H-NMR (400 MHz, CDCl3) δ: 1.63-1.75 (2H, m), 1.78-1.88 (2H, m), 2.01-2.12 (2H, m), 2.44-2.53 (2H, m), 2.67 (1H, s), 4.00-4.07 (1H, m), 6.89 (2H, d, J=8.8 Hz), 6.90 (2H, d, J=8.8 Hz), 7.51 (2H, d, J=8.8 Hz), 7.57 (2H, d, J=8.8 Hz).
IR (KBr,cm-1): 3356, 1613, 1600, 1520, 1503, 1254, 1182, 1033, 999, 966, 834.
ESI-MS: m/z= 396 (M+H)+
化合物45として、1-(4-(4-メトキシフェニル)-5-(p-トリル)チアゾール-2-イル)-4-(トリフルオロメチル)シクロヘキサン-トランス-1,4-ジオール
化合物45:1H-NMR (400 MHz, CDCl3) δ: 1.79-1.84 (2H, m), 1.90 (1H, s), 1.96-2.01 (2H, m), 2.21-2.33 (4H, m), 2.37 (3H, s), 3.28 (1H, s), 3.80 (3H, s), 6.80-6.84 (2H, m), 7.13 (2H, d, J=8.0 Hz), 7.23 (2H, d, J=8.0 Hz), 7.44-7.48 (2H, m).
IR (KBr, cm-1): 3460, 2940, 1610, 1515, 1494, 1442, 1310, 1245, 1175, 1035, 1005,837, 813
ESI-MS: m/z= 464 (M+H)+
化合物46:1H-NMR (400 MHz, CDCl3) δ: 1.90-1.96 (2H, m), 1.97 (1H, br), 2.16-2.23 (2H, m), 2.28-2.36 (4H, m), 2.37 (3H, s), 2.81 (1H, br), 3.80 (3H, s), 6.80-6.83 (2H, m), 7.14 (2H, d, J=8.0 Hz), 7.26 (2H, d, J=8.0 Hz), 7.44-7.48 (2H, m).
IR (KBr, cm-1): 3419, 2940, 1611, 1515, 1443, 1290, 1250, 1175, 1120, 1066, 993,837, 814
ESI-MS: m/z= 464 (M+H)+
化合物58として、4-ヒドロキシ-4-(1-(4-メトキシフェニル)-5-(p-トリル)-1H-ピラゾール-3-イル)-シス-シクロヘキサンカルボン酸エチル
1H-NMR (400 MHz, CDCl3) δ: 1.27 (3H, t, J=6.8 Hz), 1.85-2.09 (8H, m), 2.33 (3H, s), 2.34-2.41 (1H, m), 2.59 (1H, s), 3.80 (3H, s), 4.15 (2H, q, J=6.8 Hz), 6.38 (1H, s), 6.84 (2H, d, J=8.8 Hz), 7.09-7.09 (4H, m), 7.20 (2H, d, J=8.8 Hz).
ESI-MS: m/z= 435 (M+H)+
化合物59として、4-ヒドロキシ-4-(1-(4-メトキシフェニル)-5-(p-トリル)-1H-ピラゾール-3-イル)-シス-シクロヘキシル ジメチルカーバメート
1H-NMR (400 MHz, CDCl3) δ: 1.93-2.04 (8H, m), 2.33 (3H, s), 2.71 (1H, s), 2.92 (6H, s), 3.80 (3H, s), 4.73-4.79 (1H, m), 6.37 (1H, s), 6.84 (2H, d, J=8.8 Hz), 7.09-7.09 (4H, m), 7.20 (2H, J=8.8 Hz).
ESI-MS: m/z= 450 (M+H)+
化合物60として、シクロヘキシル 4-ヒドロキシ-4-(1-(4-メトキシフェニル)-5-(p-トリル)-1H-ピラゾール-3-イル)-シス-シクロヘキシル カーボネート
1H-NMR (400 MHz, CDCl3) δ: 1.23-1.28 (4H, m), 1.31-1.40 (2H, m), 1.44-1.56 (4H, m), 1.70-1.79 (4H, m), 1.93-2.08 (4H, m), 2.32 (3H, s), 2.82 (1H, s), 3.79 (3H, s), 4.57-4.64 (1H, m), 4.67-4.71 (1H, m), 6.38 (1H, s), 6.84 (2H, d, J=8.4 Hz), 7.08-7.08 (4H, m), 7.19 (2H, J=8.4 Hz).
ESI-MS: m/z= 505 (M+H)+
化合物63として、コハク酸モノ-4-ヒドロキシ-4-(1-(4-メトキシフェニル)-5-(p-トリル)-1H-ピラゾール-3-イル)-シス-シクロヘキシルエステル
1H-NMR (400 MHz, CDCl3) δ: 1.86-1.88 (2H, m), 1.96-2.02 (4H, m), 2.08-2.11 (3H, m), 2.32 (3H, s), 2.58-2.64 (4H, m), 3.81 (3H, s), 4.82-4.88 (1H, m), 6.38 (1H, s), 6.84 (2H, d, J=8.0 Hz), 7.09-7.09 (4H, m), 7.18 (2H, J=8.0 Hz).
ESI-MS: m/z= 479 (M+H)+
化合物64として、シクロヘキシル (4-ヒドロキシ-4-(1-(4-メトキシフェニル)-5-(p-トリル)-1H-ピラゾール-3-イル)-シス-シクロヘキシルオキシ)エチル カーボネート
1H-NMR (400 MHz, CDCl3) δ: 1.15-1.34 (9H, m), 1.48-1.65 (4H, m), 1.83-1.98 (8H, m), 2.33 (3H, s), 2.49 (1H, s), 3.52-3.58 (1H, m), 3.64-3.71 (1H, m), 3.81 (3H, s), 4.92 (1H, q, J=5.2 Hz), 6.39 (1H, s), 6.84 (2H, d, J=8.8 Hz), 7.09-7.09 (4H, m), 7.19 (2H, J=8.8 Hz).
ESI-MS: m/z= 549 (M+H)+
化合物67として、4-ヒドロキシ-4-(1-(4-メトキシフェニル)-5-(p-トリル)-1H-ピラゾール-3-イル)-シス-シクロヘキシル 2-アミノアセテート
1H-NMR (400 MHz, CDCl3) δ: 1.58-1.82 (2H, m), 1.88-2.12(9H, m), 2.33 (3H, s), 3.43 (2H, s), 3.81 (3H, s), 4.88-4.94 (1H, m), 6.37 (1H, s), 6.83-6.87 (2H, m), 7.09-7.11 (4H, m), 7.18-7.22 (2H, m).
ESI-MS: m/z= 436 (M+H)+
化合物69として、(S)-4-ヒドロキシ-4-(1-(4-メトキシフェニル)-5-(p-トリル)-1H-ピラゾール-3-イル)-シス-シクロヘキシル 2-アミノ-3-メチルブタノエート
1H-NMR (400 MHz, CDCl3) δ: 0.92 (3H, d, J=6.8 Hz), 1.02 (3H, d, J=6.8 Hz), 1.90-2.12 (9H, m), 2.34 (3H, s), 3.32-3.34 (1H, m), 3.67-3.76 (1H, m), 3.81 (3H, s), 5.41 (1H, d, J=6.4 Hz), 5.47 (1H, d, J=6.4 Hz), 6.38, (1H, s), 6.83-6.87 (2H, m), 7.09-7.12 (4H, m), 7.18-7.22 (2H, m).
ESI-MS: m/z= 490 (M-OH)+
化合物70として、4-ヒドロキシ-4-(1-(4-メトキシフェニル)-5-(p-トリル)-1H-ピラゾール-3-イル)-シス-シクロヘキシルジハイドロゲンホスフェート
1H-NMR (400 MHz, DMSO-d6) δ: 1.68-1.98 (8H, m), 2.28 (3H, s), 3.76 (3H, s), 4.13 (1H, br), 4.92 (1H, br), 6.53 (1H, s), 6.91-6.95 (2H, m), 7.08-7.17 (6H, m).
ESI-MS: m/z= 459 (M+H)+
1H-NMR (400 MHz, CDCl3) δ: 1.75-2.03 (9H, m), 2.49 (1H, m), 3.95 (4H, s).
ESI-MS: m/z= 165 (M-OH)+
1H-NMR (400 MHz, CDCl3) δ: 1.18-1.30 (1H, m), 1.47-1.74 (7H, m), 1.89-1.98 (2H, m), 2.08 (1H, brs), 2.22 (1H, brs), 2.36 (3H, s), 5.47 (1H, s), 7.19 (2H, d, J=8.0 Hz), 7.43 (2H, d, J=8.0 Hz).
ESI-MS: m/z= 227 (M-OH)+
1H-NMR (400 MHz, CDCl3) δ: 1.72-1.85 (4H, m), 1.90-2.04 (4H, m), 2.35 (3H, s), 2.55 (1H, s), 2.78 (1H, d, J=6.0 Hz), 3.93 (4H, s), 5.44 (1H, d, J=6.0 Hz), 7.17 (2H, d, J=8.0 Hz), 7.40 (2H, d, J=8.0 Hz).
ESI-MS: m/z= 285 (M-OH)+
1H-NMR (400 MHz, CDCl3) δ: 1.73-1.85 (4H, m), 1.91-2.04 (4H, m), 2.32 (1H, s), 2.52 (1H, d, J=6.1 Hz), 3.81 (3H, s), 3.94 (4H, s), 5.44 (1H, d, J=6.1 Hz), 6.89 (2H, d, J=8.5 Hz), 7.44 (2H, d, J=8.5 Hz).
1H-NMR (400 MHz, CDCl3) δ: 1.68-1.81 (4H, m), 1.86-1.90 (4H, m), 3.55 (1H, s), 3.90 (4H, s), 4.03 (1H, d, J=4.2 Hz), 5.41 (1H, d, J=4.2 Hz), 7.28 (2H, d, J=8.3 Hz), 7.41 (2H, d, J=8.3 Hz).
1H-NMR (400 MHz, CDCl3) δ:1.28-1.39 (1H, m), 1.55-1.84 (7H, m), 2.02-2.11 (2H, m), 2.23 (1H, brs), 2.43 (3H, s), 7.28 (2H, d, J=8.0 Hz), 8.02 (2H, d, J=8.0 Hz).
1H-NMR (400 MHz, CDCl3) δ: 1.79-1.85 (2H, m), 1.87-1.93 (2H, m), 2.04-2.15 (4H, m), 2.20 (1H, s), 2.43 (3H, s), 3.97 (4H, s), 7.28 (2H, d, J=8.0 Hz), 8.00 (2H, d, J=8.0 Hz).
ESI-MS: m/z= 284 (M-OH)+
中間体10として、3-(8-ヒドロキシ-1,4-ジオキサスピロ[4.5]デカン-8-イル)-1-(6-メチルピリジン-3-イル)-2-プロピン-1-オン
1H-NMR (400 MHz, CDCl3) δ: 1.76-1.83 (2H, m), 1.87-1.94 (2H, m), 2.04-2.10 (2H, m), 2.12-2.19 (2H, m), 2.30 (1H, s), 2.66 (3H, s), 3.97 (4H, s), 7.29 (1H, d, J=8.0 Hz), 8.22 (1H, dd, J=2.4, 8.0 Hz), 9.21 (1H, d, J=2.4 Hz).
ESI-MS: m/z= 284 (M-OH)+
1H-NMR (400 MHz, CDCl3) δ: 1.78-1.93 (4H, m), 2.03-2.17 (4H, m), 2.27 (1H, s), 3.89 (3H, s), 3.97 (4H, s), 6.95 (2H, d, J=9.0 Hz), 8.08 (2H, d, J=9.0 Hz).
ESI-MS: m/z= 299 (M-OH)+
1H-NMR (400 MHz, CDCl3) δ: 1.77-1.94 (4H, m), 2.04-2.19 (4H, m), 2.15 (1H, s), 3.98 (4H, s), 7.47 (2H, d, J=8.5 Hz), 8.04 (2H, d, J=8.5 Hz).
ESI-MS: m/z= 303 (M-OH)+
中間体18として、8-(1-(4-メトキシフェニル)-5-(p-トリル)-1H-ピラゾール-3-イル)-1,4-ジオキサスピロ[4.5]デカン-8-オール
1H-NMR (400 MHz, CDCl3) δ: 1.71-1.74 (2H, m), 1.99-2.25 (6H, m), 2.33 (3H, s), 2.71 (1H, s), 3.81 (3H, s), 3.96-4.01 (4H, m), 6.39 (1H, s), 6.84 (2H, d, J=8.0 Hz), 7.09 (4H, s), 7.21 (2H, d, J=8.0 Hz).
ESI-MS: m/z= 421 (M+H)+
中間体19として、8-(1-(4-メトキシフェニル)-5-(6-メチルピリジン-3-イル)-1H-ピラゾール-3-イル)-1,4-ジオキサスピロ[4.5]デカン-8-オール
1H-NMR (400 MHz, CDCl3) δ: 1.72-1.75 (2H, m), 2.00-2.03 (2H, m), 2.07-2.14 (2H, m), 2.19-2.26 (2H, m), 2.55 (3H, s), 2.65 (1H, s), 3.81 (3H, s), 3.96-4.03 (4H, m), 6.47 (1H, s), 6.86 (2H, d, J=8.8 Hz), 7.06 (1H, d, J=8.0 Hz), 7.20 (2H, d, J=8.8 Hz), 7.33 (1H, dd, J=2.2, 8.0 Hz), 8.40 (1H, d, J=2.2 Hz).
ESI-MS: m/z= 422 (M+H)+
1H-NMR (400 MHz, CDCl3) δ: 1.68-1.77 (2H, m), 1.96-2.26 (6H, m), 2.70 (1H, brs), 3.80 (3H, s), 3.81 (3H, s), 3.94-4.04 (4H, m), 6.37(1H, s), 6.81 (2H, d, J=8.8 Hz), 6.85 (2H, d, J=8.8 Hz), 7.13 (2H, d, J=8.8 Hz), 7.21 (2H, d, J=8.8 Hz).
ESI-MS: m/z= 437 (M+H)+
中間体21として、8-(5-(4-クロロフェニル)-1-(4-メトキシフェニル)-1H-ピラゾール-3-イル)-1,4-ジオキサスピロ[4.5]デカン-8-オール
1H-NMR (400 MHz, CDCl3) δ: 1.69-1.76 (2H, m), 1.97-2.25 (6H, m), 2.66 (1H, brs), 3.82 (3H, s), 3.94-4.03 (4H, m), 6.43 (1H, s), 6.85-6.87 (2H, m), 7.13 (2H, d, J=8.4 Hz), 7.19 (2H, d, J=8.4 Hz), 7.25-7.27 (2H, m).
ESI-MS: m/z= 441 (M+H)+
中間体22として、8-(1-(4-クロロフェニル)-5-(p-トリル)-1H-ピラゾール-3-イル)-1,4-ジオキサスピロ[4.5]デカン-8-オール
1H-NMR (400 MHz, CDCl3) δ: 1.71-1.75 (2H, m), 1.98-2.14 (4H, m), 2.17-2.25 (2H,m), 2.36 (3H, s), 2.62 (1H, s), 3.96-4.03 (4H, m), 6.41 (1H, s), 7.09 (2H, d, J=8.0 Hz), 7.13 (2H, d, J=8.0 Hz), 7.22-7.30 (4H, m).
ESI-MS: m/z= 407 (M-OH)+
中間体38として、1-(1-(4-メトキシフェニル)-5-(p-トリル)-1H-ピラゾール-3-イル)-シクロヘキサン-シス-1,4-ジイル ジアセタート
1H-NMR (400 MHz, CDCl3) δ: 1.74-1.82 (2H, m), 1.92-1.98 (2H, m), 2.01-2.08 (5H, m), 2.10 (3H, s), 2.32 (3H, s), 2.70-2.77 (2H, m), 3.80 (3H, s), 4.80-4.89 (1H, m), 6.38 (1H, s), 6.83 (2H, d, J=8.8 Hz), 7.08 (4H, s), 7.20 (2H, d, J=8.8 Hz).
ESI-MS: m/z= 463 (M+H)+
中間体39として、c-4-メトキシ-1-(1-(4-メトキシフェニル)-5-(p-トリル)-1H-ピラゾール-3-イル)-シクロヘキサン-r-1-イル アセタート
1H-NMR (400 MHz, CDCl3) δ: 1.60-1.68 (2H, m), 1.94-2.03 (4H, m), 2.08 (3H, s), 2.32 (3H, s), 2.69-2.76 (2H, m), 3.24-3.33 (1H, m), 3.39 (3H, s), 3.80 (3H, s), 6.37 (1H, s), 6.83 (2H, d, J=8.8 Hz), 7.08 (4H, s), 7.20 (2H, d, J=8.8 Hz).
ESI-MS: m/z= 435 (M+H)+
中間体40として、4-(4-フルオロ-1-(4-メトキシフェニル)-5-(p-トリル)-1H-ピラゾール-3-イル)-c-4-ヒドロキシ-シクロヘキサン-r-1-イル アセタート
1H-NMR (400MHz, CDCl3)δ: 1.89-2.15 (11H, m), 2.35 (3H, m), 2.73 (1H, s), 3.81 (3H, s), 4.82-4.89 (1H, m), 6.84-6.86 (2H, m), 7.10-7.18 (6H, m).
ESI-MS: m/z= 439 (M+H)+
中間体41として、1-(1-(4-メトキシフェニル)-5-(p-トリル)-1H-ピラゾール-3-イル)-4-オキソ-シクロヘキサン-1-イル アセタート
1H-NMR (400 MHz, CDCl3) δ: 2.13 (3H, s), 2.33 (3H, s), 2.44-2.52 (4H, m), 2.59-2.65 (2H, m), 2.93-2.96 (2H, m), 3.81 (3H, s), 6.45 (1H, s), 6.84 (2H, d, J=8.8 Hz), 7.08 (4H, s), 7.20 (2H, d, J=8.8 Hz).
ESI-MS: m/z= 419 (M+H)+
中間体42として、c-4-ヒドロキシ-4-(1-(4-メトキシフェニル)-5-(p-トリル)-1H-ピラゾール-3-イル)-シス-シクロヘキサン-r-1-カルバルデヒド
1H-NMR (400 MHz, CDCl3) δ: 1.88-1.96 (6H, m), 2.09-2.11 (2H, m), 2.25-2.36 (5H, m), 3.80 (3H, s), 6.39 (1H, s), 6.84 (2H, d, J=8.8 Hz), 7.09-7.14 (4H, m), 7.20 (2H, d, J=8.8 Hz), 9.66 (1H, d, J=2.0 Hz).
ESI-MS: m/z= 391 (M+H)+
1H-NMR (400 MHz, CDCl3) δ: 1.25 (3H, t, J=7.2 Hz), 1.51-1.61 (2H, m), 1.75-1.86 (4H, m), 1.90-1.98 (2H, m), 2.29-2.38 (1H, s), 3.95 (4H, s), 4.13 (2H, q, J=7.2 Hz).
ESI-MS: m/z= 215 (M+H)+
1H-NMR (400 MHz, CDCl3) δ: 1.24 (3H, t, J=7.2 Hz), 1.52-1.68 (6H, m), 2.16-2.23 (2H, m), 3.46 (2H, s), 3.88-3.96 (4H, m), 4.17 (2H, q, J=7.2 Hz), 4.49 (2H, s), 7.25-7.39 (5H, m).
ESI-MS: m/z= 335 (M+H)+
1H-NMR (400 MHz, CDCl3) δ: 1.48-1.66 (8H, m), 2.76 (1H, t, J=6.0 Hz), 3.43 (2H, s), 3.60 (2H, d, J=6.0 Hz), 3.91-3.95 (4H, m), 4.52 (2H, s), 7.27-7.38 (5H, m).
ESI-MS: m/z= 293 (M+H)+
1H-NMR (400 MHz, CDCl3) δ: 1.55-1.67 (6H, m), 2.03-2.11 (2H, m), 3.45 (2H, s), 3.90-3.95 (4H, m), 4.47 (2H, s), 7.25-7.36 (5H, m), 9.60 (1H, s).
ESI-MS: m/z= 291 (M+H)+
1H-NMR (400 MHz, CDCl3) δ: 1.52-1.71 (4H, m), 1.77-1.85 (2H, m), 1.94-2.04 (2H, m), 2.19 (1H, s), 3.38 (2H, s), 3.89-3.99 (4H, s), 4.61 (2H, s), 7.25-7.37 (5H, m).
ESI-MS: m/z= 287 (M+H)+
1H-NMR (400 MHz, CDCl3) δ: 1.62-1.71 (4H, m), 1.79-1.86 (2H, m), 1.92-2.02 (2H, m), 2.23 (1H, brs), 2.34 (3H, s), 3.41 (2H, s), 3.89-3.98 (4H, m), 4.59 (2H, m), 5.44 (1H, d, J=5.2 Hz), 7.15 (2H, d, J=8.0 Hz), 7.25-7.35 (5H, m), 7.43 (2H, d, J=8.0 Hz).
ESI-MS: m/z= 407 (M+H)+
1H-NMR (400 MHz, CDCl3) δ: 1.71-1.80 (4H, m), 1.97-2.03 (4H, m), 2.41 (3H, s), 3.52 (2H, s), 3.91-4.00 (4H, m), 4.63 (2H, m), 7.21 (2H, d, J=8.0 Hz), 7.25-7.38 (5H, m), 8.03 (2H, d, J=8.0 Hz).
ESI-MS: m/z= 405 (M+H)+
中間体50として、3-(8-(ベンジルオキシメチル)-1,4-ジオキサスピロ[4.5]デカン-8-イル)-1-(4-メトキシフェニル)-5-(p-トリル)-1H-ピラゾール
1H-NMR (400 MHz, CDCl3) δ: 1.64-1.72 (2H, m), 1.76-1.85 (2H, m), 1.89-1.98 (2H, m), 2.27-2.35 (5H, m), 3.50 (2H, s), 3.80 (3H, s), 3.90-3.99 (4H, m), 4.49 (2H, s), 6.38 (1H, s), 6.80-6.85 (2H, m), 7.06-7.31 (11H, m).
ESI-MS: m/z= 525 (M+H)+
中間体51として、4-(ベンジルオキシメチル)-4-(1-(4-メトキシフェニル)-5-(p-トリル)-1H-ピラゾール-3-イル)シクロヘキサン-1-オン
1H-NMR (400 MHz, CDCl3) δ: 2.11-2.21 (2H, m), 2.31-2.39 (5H, m), 2.52-2.68 (4H, m), 3.57 (2H, s), 3.81 (3H, s), 4.51 (2H, s), 6.44 (1H, s), 6.83-6.88 (2H, m), 7.08-7.34 (11H, m).
ESI-MS: m/z= 481 (M+H)+
1H-NMR (400 MHz, CDCl3) δ: 1.71-1.80 (2H, m), 2.01-2.11 (4H, m), 2.30-2.41 (2H, m), 2.76 (1H, s), 3.83 (3H, s), 3.84 (3H, s), 3.99 (4H, dd, J=Hz), 6.89 (2H, d, J=8.8 Hz), 6.90 (2H, d, J=8.8 Hz), 7.50 (2H, d, J=8.8 Hz), 7.56 (2H, d, J=8.8 Hz).
1H-NMR (400 MHz, CDCl3)δ: 1.53-1.61 (2H, m), 1.72-1.86 (4H, m), 1.91-1.98 (2H, m), 2.17-2.25 (1H, m), 3.95 (4H, s), 5.29 (1H, brs), 5.46 (1H, brs).
ESI-MS: m/z= 186 (M+H)+
1H-NMR (400 MHz, CDCl3)δ: 1.57-1.66 (2H, m), 1.79-1.90 (4H, m), 1.97-2.03 (2H, m), 2.64-2.72 (1H, m), 3.96 (4H, s), 6.89 (1H, brs), 7.46 (1H, brs).
ESI-MS: m/z= 202 (M+H)+
1H-NMR (400 MHz, CDCl3)δ: 1.68-1.76 (2H, m), 1.88-1.98 (4H, m), 2.18-2.24 (2H, m), 2.35 (3H, s), 3.05-3.13 (1H, m), 3.80 (3H, s), 3.99 (4H, s), 6.79-6.82 (2H, m), 7.11 (2H, d, J=8.0 Hz), 7.22 (2H, d, J=8.0 Hz), 7.43-7.46 (2H, m).
ESI-MS: m/z= 422 (M+H)+
1H-NMR (400 MHz, CDCl3)δ: 1.73-1.79 (2H, m), 2.03-2.10 (4H, m), 2.32-2.39 (2H, m), 2.37 (3H, s), 2.78 (1H, s), 3.84 (3H, s), 3.97-4.02 (4H, m), 6.88-6.92 (2H, m), 7.16 (2H, d, J=8.4 Hz), 7.47 (2H, d, J=8.4 Hz), 7.55-7.58 (2H, m).
ESI-MS: m/z= 438 (M+H)+
中間体57として、4-ヒドロキシ-4-(1-(4-メトキシフェニル)-5-(p-トリル)-1H-ピラゾール-3-イル)-シス-シクロヘキシル 2-ベンジロキシカルボニルアミノアセテート
1H-NMR (400 MHz, CDCl3) δ: 1.91-2.07 (8H, m), 2.33 (3H, s), 2.75 (1H, s), 3.80 (3H, s), 3.98-3.99 (2H, m), 4.89-4.94 (1H, m), 5.14 (2H, s), 5.33-5.35 (1H, m), 6.36 (1H, s), 6.82-6.86 (2H, m), 7.08-7.10 (4H, m), 7.17-7.21 (2H, m), 7.29-7.38 (5H, m).
ESI-MS: m/z= 552 (M-OH)+
中間体58として、中間体57と同様の方法により(S)-4-ヒドロキシ-4-(1-(4-メトキシフェニル)-5-(p-トリル)-1H-ピラゾール-3-イル)-シス-シクロヘキシル 2-(ベンジロキシカルボニルアミノ)-3-メチルブタノエートを合成した。
ESI-MS: m/z= 594 (M-OH)+
中間体59として、(S)-4-ヒドロキシ-4-(1-(4-メトキシフェニル)-5-(p-トリル)-1H-ピラゾール-3-イル)シクロヘキシロキシ)メチル 2-(ベンジロキシカルボニルアミノ)-3-メチルブタノエート
1H-NMR (400 MHz, CDCl3) δ: 0.92 (3H, d, J=6.4 Hz), 1.01 (3H, d, J=6.4 Hz), 1.88-1.99 (6H, m), 2.02-2.09 (2H, m), 2.20-2.26 (1H, m), 2.34 (3H, s), 2.50 (1H, s), 3.66-3.72 (1H, m), 3.81 (3H, s), 4.32-4.36 (1H, m), 5.12 (2H, s), 5.38 (1H, d, J=6.4 Hz), 5.50 (1H, d, J=6.4 Hz), 6.37 (1H, s), 6.83-6.87 (2H, m), 7.08-7.11 (4H, m), 7.18-7.24 (2H, m), 7.29-7.38 (5H, m).
ESI-MS: m/z= 624 (M-OH)+
中間体60として、ジベンジル 4-ヒドロキシ-4-(1-(4-メトキシフェニル)-5-(p-トリル)-1H-ピラゾール-3-イル)―シス-シクロヘキシルホスフェート
1H-NMR (400 MHz, CDCl3) δ: 1.87-2.11 (8H, m), 2.33 (3H, s), 3.79 (3H, s), 4.42-4.51 (1H, m), 5.00-5.12 (4H, m), 6.34 (1H, s), 6.81-6.87 (2H, m), 7.09 (4H, s), 7.16-7.23 (2H, m), 7.29-7.37 (10H, m).
ESI-MS: m/z= 639 (M+H)+
1H-NMR (400 MHz, CDCl3) δ: 2.33-2.43 (9H, m), 2.87-2.95 (3H, m), 3.82 (3H, s), 6.39 (1H, s), 6.86 (2H, d, J=8.8 Hz), 7.10 (4H, s), 7.22 (2H, d, J=8.8 Hz).
IR (KBr, cm-1): 3321, 2929, 1712, 1518, 1463, 1299, 1249, 1179, 1114, 1027, 961, 821.
ESI-MS: m/z= 377 (M+H)+
中間体62として、4-ヒドロキシ-4-(1-(4-メトキシフェニル)-5-(6-メチルピリジン-3-イル)-1H-ピラゾール-3-イル)-シクロヘキサン-1-オン
1H-NMR (400 MHz, CDCl3) δ: 2.34-2.44 (6H, m), 2.55 (3H, s), 2.87-2.95 (2H, m),3.18 (1H, s), 3.82 (3H, s), 6.49 (1H, s), 6.87 (2H, d, J=8.8 Hz), 7.08 (1H, d, J=8.1 Hz), 7.19 (2H, d, J=8.8 Hz), 7.35 (1H, dd, J=2.2, 8.1 Hz), 8.40 (1H, d, J=2.2 Hz).
ESI-MS: m/z= 378 (M+H)+
1H-NMR (400 MHz, CDCl3) δ: 2.30-2.45 (6H, m), 2.86-2.96 (2H, m), 2.99 (1H, s), 3.80 (3H, s), 3.82 (3H, s), 6.36 (1H, s), 6.82 (2H, d, J=8.8 Hz), 6.87 (2H, d, J=8.8 Hz), 7.13 (2H, d, J=8.8 Hz), 7.21 (2H, d, J=8.8 Hz).
ESI-MS: m/z= 393 (M+H)+
中間体64として、4-(5-(4-クロロフェニル)-1-(4-メトキシフェニル)-1H-ピラゾール-3-イル)-4-ヒドロキシ-シクロヘキサン-1-オン
1H-NMR (400 MHz, CDCl3) δ: 2.31-2.45 (6H, m), 2.85-2.98 (3H, m), 3.82 (3H, s), 6.43 (1H, s), 6.86-6.90 (2H, m), 7.14 (2H, d, J=8.8 Hz), 7.19 (2H, d, J=8.8 Hz), 7.26-7.29 (2H, m).
ESI-MS: m/z= 397 (M+H)+
1H-NMR (400 MHz, CDCl3) δ: 2.32-2.36 (4H, m), 2.36 (3H, s), 2.38-2.44 (2H, m), 2.87-2.95 (2H, m), 2.90 (1H, s), 6.41 (1H, s), 7.10 (2H, d, J=8.0 Hz), 7.14 (2H, d, J=8.0 Hz), 7.23 (2H, d, J=8.8 Hz), 7.31 (2H, d, J=8.8 Hz).
ESI-MS: m/z= 381 (M+H)+
中間体81として、4-(4-クロロ-1-(4-メトキシフェニル)-5-(p-トリル)-1H-ピラゾール-3-イル)-c-4-ヒドロキシ-シクロヘキサン-r-1-イル アセタート
1H-NMR (400MHz, CDCl3) δ: 1.92-2.04 (6H, m), 2.28-2.36 (8H, m), 3.10 (1H, s), 3.79 (3H, s), 4.85-4.88 (1H, m), 6.80-6.82 (2H, m), 7.11-7.16 (6H, m).
1H-NMR (400 MHz, CDCl3) δ: 2.32-2.54 (6H, m), 2.81-2.92 (2H, m), 3.17 (1H, m), 3.84 (6H, s), 6.90 (2H, d, J=8.8 Hz), 6.91 (2H, d, J=8.8 Hz), 7.49 (2H, d, J=8.8Hz), 7.56 (2H, d, J=8.8 Hz).
ESI-MS: m/z= 394 (M+H)+
1H-NMR (400 MHz, CDCl3)δ: 2.33-2.51 (6H, m), 2.37 (3H, s), 2.86-2.95 (2H, m), 3.50 (1H, s), 3.81 (3H, s), 6.81-6.84 (2H, m), 7.14 (2H, d, J=8.0 Hz), 7.24 (2H, d, J=8.0 Hz), 7.44-7.48 (2H, m).
ESI-MS: m/z= 394 (M+H)+
中間体84として、c-4-ヒドロキシ-1-(1-(4-メトキシフェニル)-5-(p-トリル)-1H-ピラゾール-3-イル)-シクロヘキサン-r-1-イル アセタート
1H-NMR (400 MHz, CDCl3) δ: 1.49 (1H, d, J=4.4 Hz), 1.65-1.74 (2H, m), 1.90-1.98 (4H, m), 2.10 (3H, s), 2.32 (3H, s), 2.71-2.78 (2H, m), 3.74-3.81 (4H, m), 6.37 (1H, s), 6.83 (2H, d, J=9.2 Hz), 7.08 (4H, s), 7.20 (2H, d, J=9.2 Hz).
ESI-MS: m/z= 421 (M+H)+
Claims (5)
- 一般式(I)
R3は、水素原子又は塩素原子であり、R4は、フッ素原子、ヒドロキシメチル基又はヒドロキシル基であり、
R5及びR6は、それぞれ独立して、水素原子、フッ素原子、炭素数1~3のハロアルキル基、カルボキシル基、メトキシカルボニル基、エトキシカルボニル基、炭素数1~4のアルコキシ基、ヒドロキシル基又は炭素数2~5のアルキルカルボニルオキシ基であるか、一緒になってオキソ基を形成してもよく、
R7及びR8は、それぞれ独立して、水素原子又はフッ素原子であり、
Yは、酸素原子又は硫黄原子であり、
Zは、窒素原子又はメチン基である。]
で示されるシクロヘキサン誘導体又はその薬理学的に許容される塩若しくはそのプロドラッグを有効成分として含有する、アルツハイマー病の治療剤又は予防剤。 - R1及びR2は、それぞれ独立して、トリフルオロメチル基、メチル基又はメトキシ基である、請求項1記載の治療剤又は予防剤。
- R3は、水素原子である、請求項1又は2記載の治療剤又は予防剤。
- R4は、ヒドロキシメチル基又はヒドロキシル基である、請求項1~3のいずれか一項記載の治療剤又は予防剤。
- R5及びR6は、それぞれ独立して、水素原子、フッ素原子、トリフルオロメチル基、カルボキシル基、メトキシ基、ヒドロキシル基又はアセチルオキシ基であるか、一緒になってオキソ基を形成してもよい、請求項1~4のいずれか一項記載の治療剤又は予防剤。
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR122021002784-6A BR122021002784B1 (pt) | 2010-04-28 | 2011-04-28 | Agente terapêutico ou agente profilático para a doença de alzheimer |
CA2793859A CA2793859C (en) | 2010-04-28 | 2011-04-28 | Therapeutic agent and preventative agent for alzheimer's disease |
JP2011518618A JP5682555B2 (ja) | 2010-04-28 | 2011-04-28 | アルツハイマー病の治療剤又は予防剤 |
MX2012012410A MX2012012410A (es) | 2010-04-28 | 2011-04-28 | Agente terapeutico y agente preventivo para enfermedad de alzheimer. |
KR1020127023063A KR101739881B1 (ko) | 2010-04-28 | 2011-04-28 | 알츠하이머병의 치료제 또는 예방제 |
US13/643,742 US8598212B2 (en) | 2010-04-28 | 2011-04-28 | Therapeutic agent and preventative agent for alzheimer's disease |
BR112012024346A BR112012024346A2 (pt) | 2010-04-28 | 2011-04-28 | agente terapêutico ou agente profilático para a doença de alzheimer |
AU2011246026A AU2011246026B2 (en) | 2010-04-28 | 2011-04-28 | Therapeutic agent and preventative agent for Alzheimer's disease |
RU2012150842/04A RU2560171C2 (ru) | 2010-04-28 | 2011-04-28 | Терапевтическое средство и профилактическое средство для лечения болезни альцгеймера |
EP11775099.2A EP2565184B8 (en) | 2010-04-28 | 2011-04-28 | Therapeutic agent and preventative agent for alzheimer's disease |
ES11775099.2T ES2560220T3 (es) | 2010-04-28 | 2011-04-28 | Agente terapéutico y agente preventivo para la enfermedad de Alzheimer |
CN201180020820.1A CN102858748B (zh) | 2010-04-28 | 2011-04-28 | 阿尔茨海默病的治疗剂或预防剂 |
PL11775099T PL2565184T3 (pl) | 2010-04-28 | 2011-04-28 | Środek terapeutyczny i środek zapobiegawczy przeciwko chorobie alzheimera |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010-103246 | 2010-04-28 | ||
JP2010103246 | 2010-04-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011136318A1 true WO2011136318A1 (ja) | 2011-11-03 |
Family
ID=44861614
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2011/060355 WO2011136318A1 (ja) | 2010-04-28 | 2011-04-28 | アルツハイマー病の治療剤又は予防剤 |
Country Status (13)
Country | Link |
---|---|
US (1) | US8598212B2 (ja) |
EP (1) | EP2565184B8 (ja) |
JP (1) | JP5682555B2 (ja) |
KR (1) | KR101739881B1 (ja) |
CN (1) | CN102858748B (ja) |
AU (1) | AU2011246026B2 (ja) |
BR (2) | BR112012024346A2 (ja) |
CA (1) | CA2793859C (ja) |
ES (1) | ES2560220T3 (ja) |
MX (1) | MX2012012410A (ja) |
PL (1) | PL2565184T3 (ja) |
RU (1) | RU2560171C2 (ja) |
WO (1) | WO2011136318A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015115509A1 (ja) | 2014-01-29 | 2015-08-06 | 東レ株式会社 | 多発性硬化症の治療剤又は予防剤 |
WO2018181859A1 (ja) * | 2017-03-31 | 2018-10-04 | 東レ株式会社 | 抗がん剤誘発末梢神経障害の治療剤又は予防剤 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102696318B1 (ko) | 2021-04-23 | 2024-08-20 | 주식회사 알트메디칼 | 이소퀴놀린 유도체 화합물을 유효성분으로 포함하는 미토콘드리아 기능이상으로 인한 질환의 예방 또는 치료용 조성물 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000007996A2 (en) | 1998-08-07 | 2000-02-17 | Chiron Corporation | Pyrazoles as estrogen receptor modulators |
WO2000066562A1 (en) | 1999-05-03 | 2000-11-09 | Dr. Reddy's Research Foundation | Pyrazoles having antiinflammatory activity |
WO2002051442A1 (fr) * | 2000-12-26 | 2002-07-04 | Takeda Chemical Industries, Ltd. | Co-prescriptions |
WO2007111323A1 (ja) | 2006-03-27 | 2007-10-04 | Toray Industries, Inc. | ウレイド誘導体およびその医薬用途 |
WO2008105383A1 (ja) | 2007-02-26 | 2008-09-04 | Toray Industries, Inc. | ピラゾール誘導体およびその医薬用途 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1196167B1 (en) * | 1999-07-02 | 2006-04-19 | Stuart A. Lipton | Use of p38 MAPK inhibitors in the treatment of ophthalmic conditions |
US20040097555A1 (en) * | 2000-12-26 | 2004-05-20 | Shinegori Ohkawa | Concomitant drugs |
HUP0400823A3 (en) * | 2001-04-05 | 2010-06-28 | Torrent Pharmaceuticals Ltd | Heterocyclic compounds for treating aging-related and diabetic vascular complications, their preparation and pharmaceutical compositions containing them |
US20040138296A1 (en) * | 2002-08-12 | 2004-07-15 | Pharmacia Corporation | Amyloid immunization and Cox-2 inhibitors for the treatment of alzheimer's disease |
WO2004021988A2 (en) * | 2002-09-05 | 2004-03-18 | Scios Inc. | Treatment of pain by inhibition of p38 map kinase |
TWI435874B (zh) * | 2008-10-31 | 2014-05-01 | Toray Industries | 環己烷衍生物及其醫藥用途 |
CN102822148B (zh) * | 2010-03-31 | 2015-03-11 | 东丽株式会社 | 纤维肌痛综合征的治疗剂或预防剂 |
-
2011
- 2011-04-28 AU AU2011246026A patent/AU2011246026B2/en not_active Ceased
- 2011-04-28 ES ES11775099.2T patent/ES2560220T3/es active Active
- 2011-04-28 EP EP11775099.2A patent/EP2565184B8/en not_active Not-in-force
- 2011-04-28 PL PL11775099T patent/PL2565184T3/pl unknown
- 2011-04-28 CN CN201180020820.1A patent/CN102858748B/zh not_active Expired - Fee Related
- 2011-04-28 WO PCT/JP2011/060355 patent/WO2011136318A1/ja active Application Filing
- 2011-04-28 KR KR1020127023063A patent/KR101739881B1/ko active IP Right Grant
- 2011-04-28 MX MX2012012410A patent/MX2012012410A/es active IP Right Grant
- 2011-04-28 RU RU2012150842/04A patent/RU2560171C2/ru not_active IP Right Cessation
- 2011-04-28 JP JP2011518618A patent/JP5682555B2/ja not_active Expired - Fee Related
- 2011-04-28 BR BR112012024346A patent/BR112012024346A2/pt not_active Application Discontinuation
- 2011-04-28 BR BR122021002784-6A patent/BR122021002784B1/pt active IP Right Grant
- 2011-04-28 US US13/643,742 patent/US8598212B2/en active Active
- 2011-04-28 CA CA2793859A patent/CA2793859C/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000007996A2 (en) | 1998-08-07 | 2000-02-17 | Chiron Corporation | Pyrazoles as estrogen receptor modulators |
WO2000066562A1 (en) | 1999-05-03 | 2000-11-09 | Dr. Reddy's Research Foundation | Pyrazoles having antiinflammatory activity |
WO2002051442A1 (fr) * | 2000-12-26 | 2002-07-04 | Takeda Chemical Industries, Ltd. | Co-prescriptions |
WO2007111323A1 (ja) | 2006-03-27 | 2007-10-04 | Toray Industries, Inc. | ウレイド誘導体およびその医薬用途 |
WO2008105383A1 (ja) | 2007-02-26 | 2008-09-04 | Toray Industries, Inc. | ピラゾール誘導体およびその医薬用途 |
Non-Patent Citations (17)
Title |
---|
"lyakuhin no Kaihatsu", vol. 7, 1990, HIROKAWA SHOTEN, pages: 163 - 198 |
"PROTECTIVE GROUPS IN ORGANIC SYNTHESIS", WILEY-INTERSCIENCE |
BLENNOW, LANCET, vol. 368, 2006, pages 387 |
BULLOCK, INT. J. CLIN. PRAC., vol. 59, 2005, pages 817 |
CHEN ET AL., NEUROPHARMACOLOGY, vol. 57, 2009, pages 121 |
CLAYTON ET AL., ANESTHESIOLOGY, vol. 106, 2007, pages 1019 |
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 39, 1989, pages 393 - 395 |
MALMBERG, PAIN, vol. 76, 1998, pages 215 - 222 |
MILLER, GERIATR NURS, vol. 25, 2004, pages 56 |
OGURA: "Japanese Pharmacology & Therapeutics", vol. 26, 1998, LIFE SCIENCE PUBLISHING, pages: S-1313 |
PROG. MED., vol. 5, 1985, pages 2157 - 2161 |
SCHATZBERG ET AL.: "Seishin Shinkei Yakurigagu Daijiten", 2009, NISHIMURA SHOTEN, pages: 669 |
SCHATZBERG ET AL.: "Seishin Shinkei Yakurigagu Daijiten", 2009, NISHIMURA SHOTEN, pages: 785 |
SHINODA, BEHAV. BRAIN RES., vol. 99, 1999, pages 17 |
SINIS ET AL., CLIN J PAIN, vol. 23, 2007, pages 273 |
TETRAHEDRON LETTERS, vol. 47, 2006, pages 1729 - 1731 |
TETRAHEDRON, vol. 45, 1989, pages 5703 - 5742 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015115509A1 (ja) | 2014-01-29 | 2015-08-06 | 東レ株式会社 | 多発性硬化症の治療剤又は予防剤 |
JPWO2015115509A1 (ja) * | 2014-01-29 | 2017-03-23 | 東レ株式会社 | 多発性硬化症の治療剤又は予防剤 |
US10130608B2 (en) | 2014-01-29 | 2018-11-20 | Toray Industries, Inc. | Methods of treating or preventing multiple sclerosis |
WO2018181859A1 (ja) * | 2017-03-31 | 2018-10-04 | 東レ株式会社 | 抗がん剤誘発末梢神経障害の治療剤又は予防剤 |
Also Published As
Publication number | Publication date |
---|---|
US8598212B2 (en) | 2013-12-03 |
KR101739881B1 (ko) | 2017-05-25 |
AU2011246026B2 (en) | 2014-10-30 |
EP2565184A4 (en) | 2013-09-11 |
AU2011246026A1 (en) | 2012-11-29 |
RU2560171C2 (ru) | 2015-08-20 |
BR112012024346A2 (pt) | 2016-05-24 |
CN102858748A (zh) | 2013-01-02 |
JPWO2011136318A1 (ja) | 2013-07-22 |
US20130041158A1 (en) | 2013-02-14 |
CA2793859A1 (en) | 2011-11-03 |
PL2565184T3 (pl) | 2016-06-30 |
CN102858748B (zh) | 2015-06-17 |
KR20130064717A (ko) | 2013-06-18 |
EP2565184B1 (en) | 2015-12-30 |
JP5682555B2 (ja) | 2015-03-11 |
MX2012012410A (es) | 2012-12-17 |
BR122021002784B1 (pt) | 2021-08-31 |
CA2793859C (en) | 2018-02-13 |
ES2560220T3 (es) | 2016-02-17 |
EP2565184A1 (en) | 2013-03-06 |
RU2012150842A (ru) | 2014-06-10 |
EP2565184B8 (en) | 2016-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5751168B2 (ja) | 線維筋痛症の治療剤又は予防剤 | |
JP5522031B2 (ja) | シクロヘキサン誘導体及びその医薬用途 | |
JP5682555B2 (ja) | アルツハイマー病の治療剤又は予防剤 | |
JP5783042B2 (ja) | 蓄尿障害の治療剤又は予防剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 2011518618 Country of ref document: JP Ref document number: 201180020820.1 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11775099 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 20127023063 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2793859 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011775099 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2012/012410 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13643742 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2012150842 Country of ref document: RU Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2011246026 Country of ref document: AU Date of ref document: 20110428 Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112012024346 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112012024346 Country of ref document: BR Kind code of ref document: A2 Effective date: 20120925 |